UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
FORM 10-Q
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2013March 31, 2014
 
OR
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the Transition Period from __________________   to _________________________
 
Commission File Number 001-33650
 
NEOSTEM, INC.
(Exact name of registrant as specified in its charter)
DELAWARE22-2343568
(State or other jurisdiction of(I.R.S. Employer
incorporation or organization)Identification No.)
  
420 LEXINGTON AVE, SUITE 350
NEW YORK, NEW YORK
10170
(Address of principal executive offices)(zip code)
 
Registrant’s telephone number, including area code: 212-584-4180

 (Former name, former address and former fiscal year, if changed since last report)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes     x         No     o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes  x        No     o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer     o
Accelerated filer     ox
Non-accelerated filer   o     (Do not check if a smaller reporting company)
Smaller reporting company     xo
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes  o     No  x
27,141,89434,008,862 SHARES. $.001 PAR VALUE, AS OF November 6, 2013May 8, 2014
 
(Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date)

Index

All references in this Quarterly Report on Form 10-Q to “we,” “us,” the “Company” and “NeoStem” mean NeoStem, Inc., including subsidiaries and predecessors, except where it is clear that the term refers only to NeoStem, Inc. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q containsincludes “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. Such forward-looking statements which involve known and unknown risks, and uncertainties and other factors which may cause our actual results, performance or achievements, or industry results, to be materially different from anticipated results, performance or achievements expressed or implied by such forward-looking statements. SuchWhen used in this Quarterly Report on Form 10-Q, statements that are not statements of current or historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “plan,” “intend,” “may,” “will,” “expect,” “believe,” “could,” “anticipate,” “estimate,” or “continue” or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. We remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertaintities and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity or our achievements or industry results, to be materially different from any future results, performance levels of activity or our achievements or industry results expressed or implied by such forward-looking statements. Factors that could cause our actual results to differ materially from anticipated results expressed or implied by forward-looking statements include, without limitation, , (i) our ability to manage our business despite operating losses and cash outflows; (ii) among others:

our ability to obtain sufficient capital or strategic business arrangements to fund our operations and expansion plans, including meeting our financial obligations under various licensing and other strategic arrangements, the funding of our clinical trials for AMR-001product candidates in our development programs for our Targeted Immunotherapy Program, our CD34 Cell Program and Tregs,our T Regulatory Cell Program, and the commercialization of the relevant technology; (iii)
our ability to build and maintain the management and human resources and infrastructure necessary to support the growth of our business; (iv)
our ability to integrate our acquired businesses successfully and grow such acquired businesses as anticipated, including expanding our PCT business internationally; (v)
whether a large global market is established for our cellular-based products and services and our ability to capture a meaningful share of this market; (vi) competitive factors and developments beyond our control; (vii)
scientific and medical developments beyond our control; (viii)
our ability to obtain and maintain, as applicable, appropriate governmental licenses, accreditations or certifications or comply with healthcare laws and regulations or any other adverse effect or limitations caused by government regulation of our business; (ix)
whether any of our current or future patent applications result in issued patents, the scope of those patents and our ability to obtain and maintain other rights to technology required or desirable for the conduct of our business;  (x) our ability to commercialize products without infringing the claims of third party patents;
whether any potential strategic benefits of various licensing transactions will be realized and whether any potential benefits from the acquisition of these licensed technologies will be realized; (xi)
the results of our development activities, including the results of our currentplanned Melapuldencel-T Phase 23 clinical trial, of AMR-001; (xii) our ability to complete ourPreSERVE Phase 2 clinical trial of AMR-001 and planned clinical trials;
our ability to complete our other planned clinical trials (or initiate futureother trials) in accordance with our estimated timelinetimelines due to delays associated with enrolling patients due to the novelty of the treatment, the size of the patient population and the need of patients to meet the inclusion criteria of the trial or otherwise; and (xiii)
the other factors discussed in “Risk Factors” in our Form 10-K filed with the Securities and Exchange Commission (“the SEC”) on March 11, 2013,13, 2014, and elsewhere in the Annual Report on Form 10-K.10-K; and
The CSC Acquisition and the ongoing operations of our NeoStem Oncology, LLC (see Note 15, Subsequent Events, to the interim financial statements included herein) will subject the combined company to additional risks.  Our Current Report on Form 8-K to be filed on the date hereof reporting the closing of the CSC Acquisition will contain a discussion of the risk factors related to the CSC Acquisition and our NeoStem Oncology, LLC subsidiary.

On June 28, 2013,The factors discussed herein, and in the Company’s board of directors unanimously approved a 1-for-10 reverse stock splitCompany's other periodic filings with the Securities and Exchange Commission (the “SEC”) which are available for review at www.sec.gov under “Search for Company Filings” could cause actual results and developments to be materially different from those expressed or implied by such statements. All forward-looking statements attributable to us are expressly qualified in their entirety by these and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the Company’s common stock, whichdate hereof. Except as required by law, the Company effected on July 16, 2013. All share and per share amountsundertakes no obligation to update any forward-looking statements, whether as a result of common stock, options and warrants in the accompanying financial statements have been restated for all periods to give retroactive effect to the reverse stock split.new information, future events or otherwise.


2
Index

TABLE OF CONTENTS
 
PART I- FINANCIAL INFORMATION
Page No.
   
Item 1.
Consolidated Financial Statements:
4
   
 
Consolidated Balance Sheets at September 30, 2013March 31, 2014 and December 31, 20122013

4
   
 
Consolidated Statements of Operations for the three and nine months ended September 30,March 31, 2014 and 2013 and 2012

5
   
 
Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30,March 31, 2014 and 2013 and 2012
6
   
 
Consolidated Statements of Equity for the ninethree months ended September 30, 2013March 31, 2014 and 20122013

7
   
 
Consolidated Statements of Cash Flows for the ninethree months ended September 30,March 31, 2014 and 2013 and 2012

8
   
 
Notes to Unaudited Consolidated Financial Statements
109
   
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
2421
   
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
3227
   
Item 4.
Controls and Procedures
3227
   
 
PART II- OTHER INFORMATION
 
   
Item 1.
Legal Proceedings
3428
   
Item 1A.
Risk Factors
3428
   
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
3428
   
Item 3.
Defaults Upon Senior Securities
3429
   
Item 4.
Mine Safety Disclosures
3429
   
Item 5.
Other Information
3529
   
Item 6.
Exhibits
3630
   
 
Signatures
3731

3
Index

PART I. FINANCIAL INFORMATION
Item 1. Consolidated Financial Statements

NEOSTEM, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

September 30,
2013		 December 31,
2012		March 31,
2014		 December 31,
2013
(Unaudited)  (Unaudited)  
ASSETS   
   
Current Assets 
  
 
  
Cash and cash equivalents$16,946,200
 $13,737,452
$41,359,652
 $46,133,759
Accounts receivable, net of allowance for doubtful accounts of $393,524 and $626,054 at September 30, 2013 and December 31, 2012, respectively1,394,498
 1,053,604
Accounts receivable, net of allowance for doubtful accounts of $390,118 and $391,829 at March 31, 2014 and December 31, 2013, respectively1,887,558
 1,860,835
Inventory529,366
 1,113,025
1,475,812
 1,270,223
Prepaids and other current assets1,466,677
 803,135
Prepaid expenses and other current assets1,833,082
 1,561,933
Total current assets20,336,741
 16,707,216
46,556,104
 50,826,750
Property, plant and equipment, net11,331,485
 11,153,143
13,790,672
 12,844,216
Goodwill11,117,770
 11,117,770
11,117,770
 11,117,770
Intangible assets, net14,026,919
 14,480,827
13,724,314
 13,875,617
Other assets973,294
 947,307
1,204,765
 1,151,729
Total assets$57,786,209
 $54,406,263
$86,393,625
 $89,816,082
LIABILITIES AND EQUITY 
  
 
  
Current Liabilities 
  
 
  
Accounts payable$3,091,287
 $2,555,240
$3,296,078
 $3,354,908
Accrued liabilities2,231,848
 2,284,813
2,381,625
 4,018,026
Notes payable402,813
 202,558
836,219
 381,097
Mortgages payable3,288,181
 3,438,475
216,005
 213,112
Derivative liabilities23,175
 23,175
Unearned revenues1,021,942
 1,468,341
2,033,116
 1,816,601
Total current liabilities10,036,071
 9,949,427
8,786,218
 9,806,919
Long-term Liabilities 
  
 
  
Deferred income taxes4,091,447
 3,599,122
4,426,635
 4,379,226
Notes payable348,299
 171,528
870,864
 531,164
Derivative liabilities114,108
 101,156
Mortgages payable2,967,948
 3,023,609
Acquisition-related contingent consideration7,550,000
 7,550,000
9,640,000
 9,450,000
Other long-term liabilities511,889
 214,871
635,008
 598,729
Total long-term liabilities12,615,743
 11,636,677
Total liabilities27,326,673
 27,789,647
Commitments and Contingencies

 



 

EQUITY 
  
 
  
Stockholders' Equity   
   
Preferred stock, authorized, 20,000,000 shares; Series B convertible redeemable preferred stock
liquidation value, 1/100 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2013 and December 31, 2012
100
 100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 21,193,870 and 16,375,365 shares, at September 30, 2013 and December 31, 2012, respectively21,194
 16,375
Preferred stock, authorized, 20,000,000 shares; Series B convertible redeemable preferred stock
liquidation value, 1/100 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2014 and December 31, 2013
100
 100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 28,593,410 and 27,196,537 shares, at March 31, 2014 and December 31, 2013, respectively28,594
 27,197
Additional paid-in capital260,212,091
 231,218,615
310,377,112
 299,594,525
Treasury stock, at cost(694,767) (665,600)(705,742) (705,742)
Accumulated deficit(223,839,053) (197,392,361)(250,055,662) (236,373,605)
Total NeoStem, Inc. stockholders' equity35,699,565
 33,177,129
59,644,402
 62,542,475
Noncontrolling interests(565,170) (356,970)(577,450) (516,040)
Total equity35,134,395
 32,820,159
59,066,952
 62,026,435
Total liabilities and equity$57,786,209
 $54,406,263
$86,393,625
 $89,816,082

See accompanying notes to consolidated financial statements.

4
Index

NEOSTEM, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
 (Unaudited)

 Three Months Ended September 30, Nine Months Ended September 30,
 2013 2012 2013 2012
Revenues$3,706,918
 $4,433,961
 $10,590,237
 11,578,783
Cost of revenues2,975,935
 3,747,490
 9,603,048
 9,439,185
Gross profit730,983
 686,471
 987,189
 2,139,598
        
Research and development4,486,389
 2,828,210
 11,619,843
 7,490,002
Selling, general, and administrative5,557,425
 5,947,264
 15,681,731
 17,092,493
Operating expenses10,043,814
 8,775,474
 27,301,574
 24,582,495
        
Operating loss(9,312,831) (8,089,003) (26,314,385) (22,442,897)
        
Other income (expense):       
Other income (expense), net179,605
 (74,881) 248,161
 36,924
Interest expense(98,618) (384,168) (208,023) (1,359,187)
 80,987
 (459,049) 40,138
 (1,322,263)
        
Loss from continuing operations before provision for income taxes and noncontrolling interests(9,231,844) (8,548,052) (26,274,247) (23,765,160)
Provision for income taxes44,757
 —
 492,325
 —
Net loss from continuing operations(9,276,601) (8,548,052) (26,766,572) (23,765,160)
Income (loss) from discontinued operations - net—
 152,095
 —
 (27,260,584)
Net loss(9,276,601) (8,395,957) (26,766,572) (51,025,744)
        
Less - loss from continuing operations attributable to noncontrolling interests(205,844) (59,572) (319,880) (248,294)
Less - income (loss) from discontinued operations attributable to noncontrolling interests—
 74,524
 —
 (12,513,069)
Net loss attributable to NeoStem, Inc.(9,070,757) (8,410,909) (26,446,692) (38,264,381)
Warrant inducement—
 (1,012,819) —
 (1,012,819)
Preferred dividends—
 (67,197) —
 (263,432)
Net loss attributable to NeoStem, Inc. common stockholders$(9,070,757) (9,490,925) $(26,446,692) (39,540,632)
        
Amounts Attributable to NeoStem, Inc. common stockholders:       
Loss from continuing operations$(9,070,757) (8,488,480) $(26,446,692) (23,516,866)
Income (loss) from discontinued operations - net of taxes—
 77,571
 —
 (14,747,515)
Warrant inducement—
 (1,012,819) —
 (1,012,819)
Preferred dividends—
 (67,197) —
 (263,432)
Net loss attributable to NeoStem, Inc. common stockholders$(9,070,757) (9,490,925) $(26,446,692) (39,540,632)
        
Basic and diluted income (loss) per share attributable to NeoStem, Inc. common stockholders:     
  
Continuing operations$(0.45) (0.57) $(1.43) $(1.79)
Discontinued operations$—
 0.01
 $—
 (1.12)
NeoStem, Inc. common stockholders$(0.45) (0.64) $(1.43) $(3.01)
Weighted average common shares outstanding20,203,934
 14,819,708
 18,482,413
 13,153,306
  Three Months Ended March 31,
  2014 2013
Revenues $4,055,575
 2,523,912
     
Costs and expenses:    
Cost of revenues 3,825,444
 2,392,089
Research and development 4,759,083
 3,161,326
Selling, general, and administrative 8,970,016
 5,801,872
Total operating costs and expenses 17,554,543
 11,355,287
     
Operating loss (13,498,968) (8,831,375)
     
Other income (expense):    
Other income (expense), net (189,551) 10,606
Interest expense (94,156) (43,560)
  (283,707) (32,954)
     
Loss before provision for income taxes and noncontrolling interests (13,782,675) (8,864,329)
Provision for income taxes 47,409
 —
Net loss (13,830,084) (8,864,329)
     
Less - loss attributable to noncontrolling interests (148,027) (63,754)
Net loss attributable to NeoStem, Inc. common stockholders $(13,682,057) (8,800,575)
     
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders $(0.49) $(0.53)
Weighted average common shares outstanding 28,120,847
 16,698,897

See accompanying notes to consolidated financial statements.

5
Index

NEOSTEM, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited) 

Three Months Ended September 30, Nine Months Ended September 30, Three Months Ended March 31,
2013 2012 2013 2012 2014 2013
Net loss$(9,276,601) $(8,395,957) $(26,766,572) $(51,025,744) $(13,830,084) $(8,864,329)
           
Other comprehensive income (loss):     
  
Foreign currency translation elimination on exit of segment—
 —
 —
 (169,993)
Foreign currency translation—
 (50,128) —
 317,294
Total other comprehensive (loss) income—
 (50,128) —
 147,301
 —
 —
           
Comprehensive loss(9,276,601) (8,446,085) (26,766,572) (50,878,443) (13,830,084) (8,864,329)
           
Comprehensive loss attributable to noncontrolling interests(205,844) (9,611) (319,880) (12,610,486) (148,027) (63,754)
           
Comprehensive net loss attributable to NeoStem, Inc. common stockholders$(9,070,757) $(8,436,474) $(26,446,692) $(38,267,957) $(13,682,057) $(8,800,575)
 
See accompanying notes to consolidated financial statements.

6
Index

NEOSTEM, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY
(Unaudited) 

Series B Convertible
Preferred Stock
 Common Stock 
Additional
Paid in
Capital
 
Accumulated
Other
Comprehensive
Income
 
Accumulated
Deficit
 
Treasury
Stock
 
Total
NeoStem,
Inc.
Stockholders'
Equity
 
Non-
Controlling
Interest in
Subsidiary
 
Total
Equity

Shares Amount Shares Amount 
Balance at December 31, 201110,000
 $100
 10,932,959
 $10,933
 $200,957,035
 $4,152,343
 $(143,094,854) $—
 $62,025,557
 $18,106,961
 $80,132,518
Net loss—
 —
 —
 —
 —
 —
 (38,264,381) —
 (38,264,381) (12,761,363) (51,025,744)
Foreign currency translation—
 —
 —
 —
 —
 (3,576) —
 —
 (3,576) 150,877
 147,301
Share-based compensation—
 —
 263,403
 263
 5,470,903
 —
 —
 —
 5,471,166
 —
 5,471,166
Net proceeds from issuance of common stock—
 —
 2,876,561
 2,878
 12,157,349
 —
 —
 —
 12,160,227
 —
 12,160,227
Proceeds from warrant exercises—
 —
 1,016,052
 1,016
 5,924,915
 —
 —
 —
 5,925,931
 —
 5,925,931
Warrant inducements—
 —
 145,895
 146
 (43,862) —
 —
 —
 (43,716) —
 (43,716)
Repayment of Series E Preferred Principal and Dividends—
 —
 279,238
 279
 1,201,938
 —
 (263,432) —
 938,785
 —
 938,785
Balance at September 30, 201210,000
 $100
 15,514,108
 $15,515
 $225,668,278
 $4,148,767
 $(181,622,667) $—
 $48,209,993
 $5,496,475
 $53,706,468
                     
                     
Series B Convertible
Preferred Stock
 Common Stock 
Additional
Paid in
Capital
 
Accumulated
Other
Comprehensive
Income
 
Accumulated
Deficit
 
Treasury
Stock
 
Total
NeoStem,
Inc.
Stockholders'
Equity
 
Non-
Controlling
Interest in
Subsidiary
 
Total
Equity

Series B Convertible
Preferred Stock
 Common Stock 
Additional
Paid in
Capital
 
Accumulated
Other
Comprehensive
Income
 
Accumulated
Deficit
 
Treasury
Stock
 
Total
NeoStem,
Inc.
Stockholders'
Equity
 
Non-
Controlling
Interest in
Subsidiary
 
Total
Equity

Shares Amount Shares Amount   Shares Amount Shares Amount 
Balance at December 31, 201210,000
 $100
 16,375,365
 $16,375
 $231,218,615
 $—
 $(197,392,361) $(665,600) $33,177,129
 $(356,970) $32,820,159
10,000
 $100
 16,375,365
 $16,375
 $231,218,615
 $—
 $(197,392,361) $(665,600) $33,177,129
 $(356,970) $32,820,159
Net loss—
 —
 —
 —
 —
 —
 (26,446,692) —
 (26,446,692) (319,880) (26,766,572)—
 —
 —
 —
 —
 —
 (8,800,575) —
 (8,800,575) (63,754) (8,864,329)
Share-based compensation—
 —
 451,666
 452
 5,441,166
 —
 —
 (29,167) 5,412,451
 —
 5,412,451
Equity-based compensation—
 —
 177,492
 178
 2,218,352
 —
 —
 —
 2,218,530
 —
 2,218,530
Net proceeds from issuance of common stock—
 —
 454,254
 455
 2,729,808
 —
 —
 —
 2,730,263
 —
 2,730,263
Proceeds from warrant exercises—
 —
 20,761
 21
 105,860
 —
 —
 —
 105,881
 —
 105,881
Warrant inducements—
 —
 —
 —
 (6,239) —
 —
 —
 (6,239) —
 (6,239)
Balance at March 31, 201310,000
 $100
 17,027,872
 $17,029
 $236,266,396
 $—
 $(206,192,936) $(665,600) $29,424,989
 $(420,724) $29,004,265
                     
                     
Series B Convertible
Preferred Stock
 Common Stock 
Additional
Paid in
Capital
 
Accumulated
Other
Comprehensive
Income
 
Accumulated
Deficit
 
Treasury
Stock
 
Total
NeoStem,
Inc.
Stockholders'
Equity
 
Non-
Controlling
Interest in
Subsidiary
 
Total
Equity

Shares Amount Shares Amount   
Balance at December 31, 201310,000
 $100
 27,196,537
 $27,197
 $299,594,525
 $—
 $(236,373,605) $(705,742) $62,542,475
 $(516,040) $62,026,435
Net loss—
 —
 —
 —
 —
 —
 (13,682,057) —
 (13,682,057) (148,027) (13,830,084)
Equity-based compensation—
 —
 329,698
 330
 3,893,286
 —
 —
 —
 3,893,616
 —
 3,893,616
Net proceeds from issuance of common stock—
 —
 3,949,255
 3,949
 21,513,473
 —
 —
 —
 21,517,422
 —
 21,517,422
—
 —
 804,375
 804
 5,629,821
 —
 —
 —
 5,630,625
 —
 5,630,625
Proceeds from option exercises—
 —
 16,369
 16
 86,642
 —
 —
 —
 86,658
 —
 86,658
—
 —
 12,800
 13
 71,347
 —
 —
 —
 71,360
 —
 71,360
Proceeds from warrant exercises—
 —
 401,215
 402
 2,125,889
 —
 —
 —
 2,126,291
 —
 2,126,291
—
 —
 250,000
 250
 1,274,750
 —
 —
 —
 1,275,000
 —
 1,275,000
Warrant inducements—
 —
 —
 —

(62,014)
—
 —
 —
 (62,014) —
 (62,014)
Change in ownership in subsidiary—
 —
 —
 —

(111,680) —
 —
 —
 (111,680) 111,680
 —
—
 —
 —
 —

(86,617) —
 —
 —
 (86,617) 86,617
 —
Balance at September 30, 201310,000
 $100
 21,193,870
 $21,194
 $260,212,091
 $—
 $(223,839,053) $(694,767) $35,699,565
 $(565,170) $35,134,395
Balance at March 31, 201410,000
 $100
 28,593,410
 $28,594
 $310,377,112
 $—
 $(250,055,662) $(705,742) $59,644,402
 $(577,450) $59,066,952
 
See accompanying notes to consolidated financial statements.
 

7
Index

NEOSTEM, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
 
 Nine Months Ended September 30,
 2013 2012
Cash flows from operating activities: 
  
Net loss$(26,766,572) $(51,025,744)
Loss from discontinued operations—
 27,260,584
Adjustments to reconcile net loss to net cash used in operating activities: 
  
Common stock, stock options and warrants issued as payment for compensation, services rendered5,412,451
 5,471,166
Depreciation and amortization1,197,801
 1,160,596
Amortization of preferred stock discount and issuance cost—
 1,195,217
Changes in fair value of derivative liability12,952
 (46,910)
Loss on disposal of assets—
 12,964
Bad debt (recovery) expense(232,531) 328,003
Deferred income taxes492,325
 —
Changes in operating assets and liabilities, net of the effect of acquisitions: 
  
Prepaid expenses and other current assets(663,543) 4,337
Accounts receivable(108,363) (1,112,107)
Inventory583,659
 199,700
Unearned revenues(446,399) (368,510)
Other assets421
 (187,123)
Accounts payable, accrued expenses and other current liabilities780,100
 711,997
Net cash used in operating activities - continuing operations(19,737,699) (16,395,830)
Net cash provided by operating activities - discontinued operations—
 12,168,199
Net cash used in operating activities(19,737,699) (4,227,631)
Cash flows from investing activities: 
  
Cash received in divestiture—
 2,728,000
Acquisition of property and equipment(948,644) (197,577)
Net cash (used in) provided by investing activities - continuing operations(948,644) 2,530,423
Net cash used in investing activities - discontinued operations—
 (5,218,531)
Net cash used in investing activities(948,644) (2,688,108)
Cash flows from financing activities: 
  
Proceeds from exercise of options86,658
 —
Proceeds from exercise of warrants2,126,291
 5,925,931
Net proceeds from issuance of capital stock21,517,422
 12,160,227
Repayment of mortgage loan(150,294) (141,353)
Proceeds from notes payable709,741
 223,433
Repayment of notes payable(332,713) (187,956)
Repayment of preferred stock—
 (2,258,852)
Payment of dividend—
 (56,850)
Payment for warrant inducement(62,014) (43,716)
Net cash provided by financing activities - continuing operations23,895,091
 15,620,864
Net cash used in financing activities - discontinued operations—
 (5,198,330)
Net cash provided by financing activities23,895,091
 10,422,534
Impact of changes of foreign exchange rates—
 (72,136)
Net increase in cash and cash equivalents3,208,748
 3,434,659
Cash and cash equivalents at beginning of period13,737,452
 12,745,432
Cash and cash equivalents at end of period16,946,200
 16,180,091

8
Index

    Less cash and cash equivalents of discontinued operations at end of period—
 10,789,480
Cash and cash equivalents of continuing operations at end of period$16,946,200
 $5,390,611
    
    
Supplemental Disclosure of Cash Flow Information:   
Cash paid during the period for:   
Interest$202,800
 $1,655,600
Taxes—
 1,841,400
Supplemental Schedule of non-cash investing activities: 
  
Capitalized interest—
 154,700
Supplemental schedule of non-cash financing activities   
Common stock issued pursuant to the redemption of Convertible Redeemable Series E 7% Preferred Stock—
 1,026,600
Common stock issued in payment of dividends for the Convertible Redeemable Series E 7% Preferred Stock—
 175,700
 Three Months Ended March 31,
 2014 2013
Cash flows from operating activities: 
  
Net loss$(13,830,084) $(8,864,329)
Adjustments to reconcile net loss to net cash used in operating activities: 
  
Equity-based compensation expense3,893,616
 2,218,530
Depreciation and amortization444,452
 554,954
Changes in fair value of derivative liability—
 (10,606)
Change in acquisition-related contingent consideration190,000
 —
Bad debt recovery(1,711) —
Deferred income taxes47,409
 —
Changes in operating assets and liabilities: 
  
Prepaid expenses and other current assets(271,149) (192,009)
Accounts receivable(25,012) 167,444
Inventory(205,589) (428,549)
Unearned revenues216,515
 346,912
Other assets(53,035) (22,986)
Accounts payable, accrued expenses and other liabilities(1,658,952) (905,094)
Net cash used in operating activities(11,253,540) (7,135,733)
Cash flows from investing activities: 
  
Acquisition of property and equipment(1,239,606) (53,571)
Net cash used in investing activities(1,239,606) (53,571)
Cash flows from financing activities: 
  
Proceeds from exercise of options71,360
 —
Proceeds from exercise of warrants1,275,000
 105,881
Net proceeds from issuance of common stock5,630,625
 2,730,262
Repayment of mortgage loan(52,768) (43,446)
Proceeds from notes payable958,014
 —
Repayment of notes payable(163,192) (81,015)
Payment for warrant inducement—
 (6,239)
Net cash provided by financing activities7,719,039
 2,705,443
Net decrease in cash and cash equivalents(4,774,107) (4,483,861)
Cash and cash equivalents at beginning of period46,133,759
 13,737,452
Cash and cash equivalents at end of period41,359,652
 9,253,591
    
    
Supplemental Disclosure of Cash Flow Information:   
Cash paid during the period for:   
Interest$93,100
 $95,700
Taxes—
 —
 
See accompanying notes to consolidated financial statements.
 

98
Index

NEOSTEM, INC. AND SUBSIDIARIES
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note 1  – The Business
 
Overview
 
NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a leader in the emerging cellular therapy industry. CellularWe are pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. We have multiple cell therapy addressesplatforms that work to address the process by which newpathology of disease using a person's own cells are introduced into a tissueto amplify the body's natural repair mechanisms including enhancing the destruction of cancer initiating cells, repairing and administered to prevent or treat disease, or regeneratereplacing damaged or aged tissue. Modern cell-based therapies have progressed from the first recorded human to human blood transfusion 200 years ago through to the advanced cellular therapies of today including bone marrowtissue, cells and organ transplantation, tissue bankingorgans and reproductive in vitro fertilization and future therapies being investigated to treat cancer, cardiologic, neurologic, ophthalmic and orthopedic diseases among others.restoring their normal function. We anticipatebelieve that cellular therapiescell therapy will haveplay a large role in changing the natural history of diseases as more breakthrough therapies are developed, ultimately lessening the fight against chronicoverall burden of disease on patients and in lesseningtheir families as well as the economic burden that these diseases pose toimpose upon modern society.

Our business model includes the development of novel proprietary cell therapy products, as well as operating a revenue-generating contract development and manufacturing organization (“CDMO”)service business that we leverage for the development of our therapeutics while providing servicesservice to othersother companies in the regenerative medicine industry.cell therapy industry developing products. The combination of aour own therapeutic development business and a revenue-generating service provider business provides the Company with unique capabilities for cost effective in-house product development and immediate revenue and future cash flow generation.to help underwrite our internal development programs. This business model enables the Company to be opportunistic in growing its pipeline as evidenced by the Company's acquisition in May 2014 through the issuance of equity of California Stem Cell, Inc. ("CSC"), a cell biotechnology corporation that is developing cellular immunotherapies for cancer, an area we view to be one of the most promising sub-sectors in biotechnology. CSC, now known as NeoStem Oncology, LLC, is driving the Company's Targeted Immunotherapy Program for cancer through the development of its lead product candidate, Melapuldencel-T, to treat Stage IV or recurrent melanoma. The Phase 3 protocol is the subject of a Special Protocol Assessment (SPA), indicating that the Food and Drug Administration ("FDA") is in agreement with the design, clinical endpoints, and planned clinical analyses of the Phase 3 trial that will serve as the basis for a Biologics License Application ("BLA"). This protocol calls for enrolling 250 patients and is expected to be initiated in 2014.

We are currently developing therapies to address ischemia through our CD34 Cell Program. Ischemia occurs when the supply of oxygenated blood in the body is restricted. We seek to reverse this restriction through the development and formation of new blood vessels. AMR-001 is our most clinically advanced product candidate in our CD34 Cell Program and is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack) ("AMI"). In December 2013, the Company completed enrollment in its PreSERVE AMI study. PreSERVE AMI is a randomized, double-blinded, placebo-controlled Phase 2 clinical trial testing AMR-001, an autologous (donor and recipient are the same) adult stem cell product for the treatment of patients with left ventricular dysfunction following acute ST segment elevation myocardial infarction (STEMI). With the last patient of the planned 160 patient trial infused in late December 2013, we expect the last patient six-month follow-up to occur in June 2014. Once the primary end point six-month data is collected, the data set will be locked and analysis will begin with a submission for a possible presentation of the study at the American Heart Association's Scientific Sessions to be held November 15-19, 2014. If approved by Food and Drug Administration (the "FDA ") and/or other worldwide regulatory agencies following successful completion of further trials, AMR-001 would address a significant medical need for which there is currently no effective treatment, potentially improving longevity and quality of life for those suffering a STEMI, and positioning the Company to capture a meaningful share of this worldwide market. We also expect to advance the technology into other clinical indications such as chronic heart failure ("CHF"), traumatic brain injury ("TBI"), and/or critical limb ischemia ("CLI").

Another platform technology we are developing utilizes T Regulatory Cells ("Tregs") to treat diseases caused by imbalances in an individual's immune system.  In collaborating with Becton-Dickinson and the University of California, San Francisco, we are utilizing this technology platform of our majority-owned subsidiary, Athelos Corporation ("Athelos"), to restore immune balance by enhancing Treg cell number and function.  Tregs are a natural part of the human immune system and regulate the activity of T effector cells, the cells that are responsible for protecting the body from viruses and  other foreign antigen exposure. When Tregs function properly, only harmful foreign materials are attacked by T effector cells. In autoimmune disease it is thought that deficient Treg activity permits the T effector cells to attack the body's own tissues, and in allergic diseases, like asthma, the immune system overreacts to harmless foreign substances. We plan to initiate a Phase 2 study of Treg based therapeutics  to treat type 1 diabetes in 2014. We also plan to initiate a Phase 1 study in Canada of Treg based therapeutics in support of a steroid resistant asthma indication in 2014.

Pre-clinical assets include our VSEL TM (Very Small Embryonic Like) Technology regenerative medicine platform. Regenerative medicine holds the promise of improving clinical outcomes and reducing overall  healthcare costs.  We are working

9
Index

on a Department of Defense funded study of VSELsTM for the treatment of chronic wounds. Other preclinical work with VSELsTM includes exploring macular degeneration as a target indication.

Progenitor Cell Therapy, LLC our("PCT") is a contract manufacturer that generates revenue. This wholly owned subsidiary, (“PCT”),which we acquired in 2011, is a leading CDMOan industry leader in the cellular therapy industry.providing high quality manufacturing capabilities and support to developers of cell-based therapies to enable them to improve efficiencies and profitability and reduce capital investment for their own development activities. Since its inception more than 15 years ago, PCT has provided pre-clinical and clinical current Good Manufacturing Practice (“cGMP”) development and manufacturing services to overmore than 100 clientsclients. PCT has experience advancing regenerative medicine product candidates from product inception through rigorous quality standards all the way through to human testing.testing, BLA filing and FDA product approval. PCT's core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, engineering and innovation services, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. PCT has two cGMP, state-of-the art cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Expansion work currently in progress at PCT's New Jersey and California facilities is expected to be completed during the first quarter of 2014. The Company intends to pursueis pursuing commercial expansion of our manufacturing operations both in the U.S. and internationally. Additionally, with the acquisition of CSC, PCT can leverage CSC's additional manufacturing capacity in Irvine, California as well as the personnel experience and expertise in immunotherapy to provide additional manufacturing and /or development work to advance NeoStem's platform technology as well as technologies of PCT's client base.

Our wholly-owned subsidiary, Amorcyte, LLC (“Amorcyte”), is developing AMR-001 forStrategic acquisitions have been the treatmentcornerstone of cardiovascular disease. AMR-001 represents Amorcyte's most clinically advanced therapeutic product candidateNeoStem’s growth and enrollment for the Phase 2 PreSERVE clinical trialhave been selected in order to investigate AMR-001's safety and efficacy in preserving heart function after a particular type of acute myocardial infarction (“AMI”) commenced in 2012. We are on trackprovide value to complete patient enrollment for this study in 2013 with the first data readout expected six to eight months after the last patient is infused. If approvedstockholders by the U.S. Food and Drug Administration ("FDA") and/or other worldwide regulatory agencies, AMR-001 would address a significant unmet medical need in the treatment of AMI, potentially improving the quality and longevity of life for those afflicted, and positioning the Company to capture a meaningful sharetaking advantage of the worldwide AMIinfrastructure we have created which includes strong development, regulatory and manufacturing expertise. By adding Melapuldencel-T, a late stage novel proprietary cancer cell therapy market. Potential congestive heart failure and traumatic brain injury indicationsinto our pipeline, we look to further advance towards our goal of delivering transformative cell based therapies to the market to help patients suffering from life-threatening medical conditions. Coupled with our best in class manufacturing capability, the stage is set for AMR-001 are also being explored.

Through our majority-owned subsidiary, Athelos Corporation (“Athelos”), we are collaborating with Becton-Dickinson and the University of California, San Francisco in early stageus to realize meaningful clinical development of a therapy that utilizes T-cells,and manufacturing efficiencies, further positioning NeoStem to treat autoimmune and inflammatory conditions. We plan to file an Investigational New Drug Application ("IND") to investigate the clinical feasibility of nTreg-based therapeutics to prevent and/or treat steroid resistant asthma (preparing for Phase 1b/2a trial). Through INDs sponsored by UCSF we also plan to study nTreg-based therapeutics in prevention and/or treatment of type 1 diabetes (Phase 2 IND in preparation), and solid organ transplantation tolerance (Phase 1 IND submitted).

Pre-clinical assets include our VSELTM(Very Small Embryonic Like) Technology platform. We expect to file an IND with the FDA to initiate a National Institutes of Health ("NIH") funded human clinical study to investigate the impact of VSELsTMin a tissue repair application. We are also working on a Department of Defense funded study of VSELsTMfor the treatment of chronic wounds. Other preclinical work with VSELsTMincludes exploring macular degeneration as a target indication.

NeoStem's origins are in adult stem cell collection and storage and we believe that as new therapeutics are developed utilizing one's own stored cells (autologous), the market penetration rate for the collection and storage business may rise sharply from its current low single digits percentage level, allowing our developing network to scale rapidly if the demand grows.

In 2011, we operated our business in three reportable segments: (i) Cell Therapy — United States; (ii) Regenerative Medicine — China; and (iii) Pharmaceutical Manufacturing — China. In 2012, we exited our operations in China. Effective

10
Index

March 31, 2012, we no longer operated in the Regenerative Medicine – China reportable segment, which was reported in discontinued operations in 2012 (see Note 14). On November 13, 2012, we completed the sale of our 51% interest in Suzhou Erye, which represented the operations in our Pharmaceutical Manufacturing - China segment, and is also reported in discontinued operations (see Note 14). As a result, we currently operate in a single reporting segment - Cell Therapy, which will focus on CDMO and cell therapy development programs.

We believe that NeoStem is ideally positioned to be an integrated leader inlead the cell therapy industry. We have significant basic research and development capabilities, manufacturing facilities on both the east and west coast of the United States, the support of regulatory and logistical expertise and a talented and experienced clinical team. We believe this expertise will allow us to achieve our mission of becoming the premier cell therapy company.


Basis of Presentation
 
The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”) for interim financial information and with the instructions to Form 10-Q and Article 810 of Regulation S-X of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of September 30, 2013March 31, 2014 and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 20122013 and 20112012 included in our Annual Report on Form 10-K for the year ended December 31, 2012.2013. Operating results for the ninethree months ended September 30, 2013March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013.2014.
    
Use of Estimates
 
The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.
 
Reclassifications
Certain reclassifications have been made to the Consolidated Financial Statements and Notes to the Consolidated Financial Statements for the three months ended March 31, 2013 to conform to the presentation for the three months ended March 31, 2014.

Principles of Consolidation
 
The Consolidated Financial Statements include the accounts of NeoStem, Inc. and its wholly owned and partially owned subsidiaries and affiliates as listed below, as well as the operations of our former Regenerative Medicine - China segment through the deconsolidation date on March 31, 2012 (see Note 14), and the operations of our former Pharmaceutical Manufacturing - China reporting segment through November 13, 2012, representing the date which the segment was sold (see Note 14). These former segments are reported in discontinued operations.below.
 

10
Index

Entity Percentage of Ownership Location
NeoStem, Inc. Parent  Company United States of America
NeoStem Therapies, Inc. 100% United States of America
Stem Cell Technologies, Inc. 100% United States of America
Amorcyte, LLC 100% United States of America
Progenitor Cell Therapy, LLC (PCT) 100% United States of America
NeoStem Family Storage, LLC 100% United States of America
Athelos Corporation (1) 83.3%90% United States of America
PCT Allendale, LLC100%United States of America
NeoStem Oncology, LLC (2) 100% United States of America

(1) Pursuant to the Stock Purchase Agreement signed in March 2011, our initial ownership in Athelos was 80.1%, and Becton Dickinson's ("BD") initial minority ownership was 19.9%. Per the Agreement, BD will be diluted based on new investment in Athelos by us (subject to certain anti-dilution provisions). As of September 30, 2013March 31, 2014, BD's ownership interest in Athelos was decreased to 16.7%10.0%, and our ownership increased to 83.3%90.0%. As a result in the change in ownership, approximately $0.1 million was transferred from additional paid in capital to non-controlling interests.


11(2) On
May 8, 2014, NeoStem acquired CSC, now known as NeoStem Oncology, LLC (see Note 15, Subsequent Events). Accordingly, the accounts of NeoStem Oncology, LLC are not included in the Company's consolidated financial position as of March 31, 2014 and the results of its consolidated operations and cash flows for the three months endedMarch 31, 2014 and 2013.

Index

Note 2 – Summary of Significant Accounting Policies
 
In addition to the policies below, our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2012.2013. There were no changes during the ninethree months ended September 30, 2013March 31, 2014.

Cash and Cash Equivalents

Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.


Accounts Receivable
 
Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk.
 
Inventories
The Company, through its PCT subsidiary, regularly enters into contracts with clients for services that have multiple stages and are dependent on one another to complete the contract and recognize revenue. The Company's inventory represents work in process for costs incurred on such projects at PCT that have not been completed. The Company reviews these projects periodically to determine that the value of each project is stated at the lower of cost or market.

Goodwill and Other Intangible Assets  

Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company’s intangible assets with an indefinite life are related to in process research and development ("IPR&D") for AMR-001, the clinical candidate acquired in the Amorcyte acquisition, as the Company expects this research and development to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. AmortizedIntangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets consist

11
Index

with indefinite useful lives. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of customer lists, manufacturing technology,the associated R&D efforts. If and tradename, as well as patentswhen development is complete, which generally occurs if and rightswhen regulatory approval to market a product is obtained, the associated primarily with the VSELTM Technology. These intangible assets arewould be deemed finite-lived and would then be amortized based on a straight line basis over their respective estimated useful lives.lives at that point in time.

The Company reviews goodwill and indefinite-lived intangible assets at least annually for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. The Company tests its goodwill and indefinite-lived intangible assets each year on December 31. The Company reviews the carrying value of goodwill and indefinite-lived intangible assets utilizing a discounted cash flow model, and, where appropriate, a market value approach is also utilized to supplement the discounted cash flow model. The Company makes assumptions regarding estimated future cash flows, discount rates, long-term growth rates and market values to determine each reporting unit’s estimated fair value. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. In accordance with it's accounting policy, the Company tested goodwill and indefinite-lived intangible assets for impairment as of December 31, 2013 and 2012 for its two reporting units, and concluded there was no risk of failing step 1 of the goodwill impairment testing evaluation, and that indefinite-lived intangible assets were not impaired.

Amortized intangible assets consist of customer lists, manufacturing technology, and tradename, as well as patents and rights associated primarily with the VSEL™ Technology. These intangible assets are amortized on a straight line basis over their respective useful lives.


Revenue Recognition
 
Clinical Services: The Company recognizes revenue for its (i) cell process development and (ii) cellclinical manufacturing services based on the terms of individual contracts.

Revenues associated with cell process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. We recognize revenues for cell development services when all of the following conditions are met:

persuasive evidence of an arrangement exists;
delivery has occurred or the services have been rendered;
the fee is fixed or determinable; and
collectability is probable.

The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform.


12
Index

CellClinical manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when efforts are expended or contractual terms have been met.

Some client agreements include multiple elements, comprised of cell process development and cellclinical manufacturing services. The Company believes that cell process development and cellclinical manufacturing services each have stand-alone value because these services can be provided separately by other companies. In accordance with ASC Update No. 2009-13, “Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements,” the Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price. 

Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company

12
Index

bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the three months ended September 30, 2013March 31, 2014 and 20122013, clinical services reimbursements were $0.60.7 million and $0.9 million, respectively. For the nine months endedSeptember 30, 2013 and 2012, clinical services reimbursements were $1.4 million and $2.90.4 million, respectively.
 
Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of cord blood and autologous adult stem cells when the cryopreservation process is completed which is approximately twenty-four hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments.

Note 3 – Cash and Cash Equivalents
 
As of September 30, 2013March 31, 2014 and December 31, 20122013, the Company had cash and cash equivalents of approximately $16.941.4 million and $13.746.1 million, respectively, including bank deposits of approximately $0.7 million and $0.8 million, respectively, covered by the Federal Deposit Insurance Corporation.
 
Note 4 – Inventories
 
Inventories, representing work in process for costs incurred on projects at PCT that have not been completed, were $0.51.5 million and $1.11.3 million as of September 30, 2013March 31, 2014 and December 31, 20122013, respectively. The Company also has deferred revenue of approximately $0.71.6 million and $1.21.5 million of advance billings received as of September 30, 2013March 31, 2014 and December 31, 20122013, respectively, related to these contracts.
 
Note 5 – Loss Per Share
 
For the three months endedMarch 31, 2014 and nine months endedSeptember 30, 2013 and 2012, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share. At September 30, 2013March 31, 2014 and 20122013, the Company excluded the following potentially dilutive securities:
September 30,March 31,
2013 20122014 2013
Stock Options2,840,668
 2,238,964
3,912,697
 2,631,181
Warrants5,054,302
 5,631,418
4,491,028
 5,501,055
Series E Preferred Stock, Common stock equivalents—
 236,480
Restricted Shares92,000
 23,200
175,731
 35,500
 
Note 6 – Fair Value Measurements
 
Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:
 
Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
 

13
Index

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.
 
Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.
 
The Company determined the fair value of the warrant derivative liabilities to be level 3 inputs. These inputs require material subjectivity because value is derived through the use of a lattice model that values the derivatives based on probability weighted discounted cash flows.

The Company also determined the fair value of contingentContingent consideration initiallywas recognized on October 17, 2011 in connection with the Company's acquisition of Amorcyte,Amorcyte. The contingent consideration obligations relates to earn out payments equal to 10% of the net sales of Amorcyte’s lead product

13
Index

candidate AMR-001 (in the event of and following the date of first commercial sale of AMR-001), provided that in the event NeoStem sublicenses AMR-001, the applicable earn out payment will be level 3 inputs. equal to 30% of any sublicensing fees, and provided further that NeoStem will be entitled to recover direct out-of-pocket clinical development costs not previously paid or reimbursed and any costs, expenses, liabilities and settlement amounts arising out of claims of patent infringement or otherwise challenging Amorcyte’s right to use intellectual property, by reducing any earn out payments due by 50% until such costs have been recouped in full (the “Earn Out Payments”).

The fair value of contingent consideration obligations is determined using Level 3 inputs, and is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. The value of our contingent consideration was initially calculated using a discount rate of 30%. We base the timing to complete the development and approval of this product on the current development stage of the product and the inherent difficulties and uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. Changes in the fair value of the contingent consideration obligations are recorded in our consolidated statement of operations. The contingent consideration fair value increased from $9.5 million as of December 31, 2013 to $9.6 million as of March 31, 2014. The change in estimated fair value is based the impact of the time progression through the Phase 2 clinical trial from December 31, 2013 to March 31, 2014.

The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2013March 31, 2014, and December 31, 20122013 (in thousands):
 
September 30, 2013March 31, 2014
Fair Value Measurements Using Fair Value HierarchyFair Value Measurements Using Fair Value Hierarchy
Level 1 Level 2 Level 3Level 1 Level 2 Level 3
Warrant derivative liabilities$—
 $—
 $114.1
$—
 $—
 $23.2
Contingent consideration—
 —
 7,550.0
Acquisition-related contingent consideration—
 —
 9,640.0
 
December 31, 2012December 31, 2013
Fair Value Measurements Using Fair Value HierarchyFair Value Measurements Using Fair Value Hierarchy
Level 1 Level 2 Level 3Level 1 Level 2 Level 3
Warrant derivative liabilities$—
 $—
 $101.2
$—
 $—
 $23.2
Contingent consideration—
 —
 7,550.0
Acquisition-related contingent consideration—
 —
 9,450.0
 
For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the three and nine months ended September 30, 2013March 31, 2014 by type of instrument (in thousands):
 
Three Months Ended Nine Months Ended Three Months Ended
September 30, 2013 September 30, 2013 March 31, 2014
Warrants Contingent Consideration Warrants Contingent Consideration Warrants Acquisition-Related Contingent Consideration
Beginning liability balance$32.6
 $7,550.0
 $101.2
 $7,550.0
 $23.2
 $9,450.0
Change in fair value recorded in earnings81.5
 —
 12.9
 —
 —
 190.0
Ending liability balance$114.1
 $7,550.0
 $114.1
 $7,550.0
 $23.2
 $9,640.0


14
Index

Some of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, accounts receivable, accounts payablepayable. Our long-term debt and notes payable are carried at cost and long-term notes payable and mortgages.approximate fair value due to their variable or fixed interest rates, which are consistent with the interest rates in the market.

14
Index



Note 7 – Goodwill and Other Intangible Assets
 
The Company's goodwill was $11.1 million as of September 30, 2013March 31, 2014 and December 31, 20122013.
 
The Company's intangible assets and related accumulated amortization as of September 30, 2013March 31, 2014 and December 31, 20122013 consisted of the following (in thousands):
 
 September 30, 2013 December 31, 2012 March 31, 2014 December 31, 2013
Useful Life Gross Accumulated Amortization Net Gross Accumulated Amortization NetUseful Life Gross Accumulated Amortization Net Gross Accumulated Amortization Net
Customer list10 years $1,000.0
 $(270.1) $729.9
 $1,000.0
 $(195.1) $804.9
10 years $1,000.0
 $(320.1) $679.9
 $1,000.0
 $(295.1) $704.9
Manufacturing technology10 years 3,900.0
 (1,053.4) 2,846.6
 3,900.0
 (760.9) 3,139.1
10 years 3,900.0
 (1,248.4) 2,651.6
 3,900.0
 (1,150.9) 2,749.1
Tradename10 years 800.0
 (216.1) 583.9
 800.0
 (156.1) 643.9
10 years 800.0
 (256.1) 543.9
 800.0
 (236.1) 563.9
In process R&DIndefinite 9,400.0
 —
 9,400.0
 9,400.0
 —
 9,400.0
Indefinite 9,400.0
 —
 9,400.0
 9,400.0
 —
 9,400.0
VSEL patent rights19 years 669.0
 (202.5) 466.5
 669.0
 (176.1) 492.9
19 years 669.0
 (220.1) 448.9
 669.0
 (211.3) 457.7
Total Intangible Assets $15,769.0
 $(1,742.1) $14,026.9
 $15,769.0
 $(1,288.2) $14,480.8
 $15,769.0
 $(2,044.7) $13,724.3
 $15,769.0
 $(1,893.4) $13,875.6
                        
 
Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):
 
Three Months Ended September 30, Nine Months Ended September 30, Three Months Ended March 31,
2013 2012 2013 2012 2014 2013
Cost of revenue$97.5
 $97.5
 $292.5
 $292.5
 $79.2
 $97.5
Research and development8.8
 8.8
 26.4
 26.4
 27.1
 8.8
Selling, general and administrative45.0
 45.0
 135.0
 135.0
 45.0
 45.0
Total$151.3
 $151.3
 $453.9
 $453.9
 $151.3
 $151.3

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):

2013$151.3
2014605.2
$453.9
2015605.2
605.2
2016605.2
605.2
2017605.2
605.2
2018605.2
Thereafter11,454.8
10,849.6
$14,026.9
$13,724.3


Note 8 – Accrued Liabilities

Accrued liabilities as of September 30, 2013March 31, 2014 and December 31, 20122013 were as follows (in thousands):
 March 31, 2014 December 31, 2013
Salaries, employee benefits and related taxes$846.4
 $2,325.8
Professional fees775.4
 544.8
License Fees200.0
 500.0
Other559.8
 647.4
 $2,381.6
 $4,018.0

15
Index

 September 30, 2013 December 31, 2012
Salaries, employee benefits and related taxes$920.8
 $1,597.2
Professional fees654.9
 606.6
Other656.1
 81.0
 $2,231.8
 $2,284.8

Note 9 – Debt
 
Notes Payable
 
As of September 30, 2013March 31, 2014 and December 31, 20122013, the Company had notes payable of approximately $0.81.7 million and $0.40.9 million, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to three years.
 
Mortgages Payable
 
OnIn October 31, 2007, PCT issued a note to borrow $3.1$3.1 million (the “Note”“First Mortgage”) in connection with its $3.8$3.8 million purchase of condominium units in an existing building in Allendale, New Jersey (the “Property”) that PCT uses as a laboratory and stem cell processing facility. The NoteFirst Mortgage is payable in 239 consecutive monthly payments of principal and interest, based on a 20 year amortization schedule; and one final payment of all outstanding principal plus accrued interest then due. The current monthly installment is $20,766,$20,766, which includes interest at an initial rate of 5.00%; the interest rate and monthly installments payments are subject to adjustment on October 1, 2017. On that date, upon prior written notice, the lender has the option to declare the entire outstanding principal balance, together with all outstanding interest, due and payable in full. The NoteFirst Mortgage is secured by substantially all of the assets of PCT, including a first mortgage on the Property and assignment of an amount approximately equal to eighteen months debt service held in escrow. The Note matures on October 1, 2027 if not called by the lender on October 1, 2017. The note isFirst Mortgage had previously been subject to certain debt service coverage and total debt to tangible net worth financial covenant ratios measured semi-annually. PCT was not in compliance with such covenants at the measurement date of December 31, 2012, and June 30, 2013, and obtained a covenant waiver letter from the lender for each period. The outstanding balance was approximately $$2.4 million and 2.5 million at September 30, 2013,March 31, 2014 and $2.6 million at December 31, 2012,2013, respectively, of which $0.1 million$128,300 is payable within twelve months as of September 30, 2013. The mortgage is classified as a current liability.March 31, 2014.

OnIn December 6, 2010 PCT Allendale, a wholly-owned subsidiary of PCT, entered into a note for a second mortgage in the amount of $1$1 million (the "Second Mortgage") on the Allendale Property with TD Bank, N.A. This loan is guaranteed byThe initial guarantors of the Second Mortgage were PCT, DomaniCell (a wholly-owned subsidiary of PCT, now known as NeoStem Family Storage, LLC), Northern New JerseyRegional Cancer Care Associates (“NNJCA”)LLC and certain partners of NNJCA and isits partners. The Second Mortgage had been subject to an annual financial covenant starting December 31, 2011. PCT was not in compliance with such covenants at the measurement date of December 31, 2012, and obtained a covenant waiver letter from the lender. The loanSecond Mortgage is for 124 months at a fixed rate of 6% for the first 64 months. The loan is callable for a certain period prior to the interest reset date. The outstanding balance was approximately $0.8$0.7 million and $0.8 million at September 30, 2013,March 31, 2014 and $0.8 million at December 31, 2012,2013, respectively, of which $0.1 million$87,700 is payable within twelve months as of September 30,March 31, 2014.

In December 2013,. the Company modified both the First Mortgage and Second Mortgage with TD Bank, N.A., whereby (i) prior debt service coverage and total debt to tangible net worth financial covenant ratios were replaced with a minimum unencumbered liquidity covenant, and (ii) prior guarantors were released (see Note 13) and replaced with NeoStem, PCT, and NeoStem Family Storage. The mortgageCompany is classified as a current liability.in compliance with the new minimum unencumbered liquidity covenant.

Note 10 – Preferred Stock
Convertible Redeemable Series E 7% Preferred Stock
On November 19, 2010, the Company sold 10,582,011 Preferred Offering Units consisting of (i) 10,582,011 shares (“Preferred Shares”) of Series E 7% Senior Convertible Preferred Stock (the “Series E Preferred Stock”), par value $0.01 per share, of the Company, (ii) Class E Warrants to purchase an aggregate of 132,249 shares of Common Stock, adjusted to an aggregate of 199,031 shares as of September 30, 2013; and (iii) an aggregate of 16,442 shares of Common Stock. Each Preferred Offering Unit was priced at $0.945 and total gross and net proceeds received by the Company were $10.0 million and $8.9 million, respectively.
Monthly dividend and principal payments began in March 2011, and continued each month thereafter with the final payment due in May 2013. In October 2012, the Company completed the redemption of all 2,351,558 Series E Preferred Stock shares then remaining outstanding , for an aggregate cash redemption price of approximately $3.4 million, $2.5 million of which was funded by money placed into escrow when the Series E Preferred stock was issued in November 2010. The cash redemption included the repayment of $3.1 million outstanding principal, an additional early redemption premium of $0.2 million, which was included in dividends, and $36,000 of accrued interest.

16
Index


The Company recorded the fair value of the warrants as a long-term derivative liability. The fair values of the warrant derivatives as of September 30, 2013 and December 31, 2012 were $114,100 and $101,200, respectively. The Company reports changes in the fair value of the warrant derivative in earnings within other income (expense), net (see Note 6).

Note 1110 – Shareholders' Equity

Reverse Stock Split

On June 28, 2013, pursuant to prior shareholder authorization, the Company’s board of directors unanimously approved a 1-for-10 reverse stock split of the Company’s common stock, which the Company effected on July 16, 2013. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods to give retroactive effect to the reverse stock split. The shares of common stock retained a par value of $0.001 per share. Accordingly, the stockholders’ deficit reflects the reverse stock split by reclassifying from “common stock” to “Additional paid-in capital” an amount equal to the par value of the decreased shares resulting from the reverse stock split.

Equity Issuances

In September 2011, the Company entered into a Common Stockcommon stock purchase agreement (the “Initial Purchase Agreement, (the “Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which providesprovided that subject to certain terms and conditions, Aspire Capital iswas committed to purchase up to an aggregate of $20.0 million worth of shares of the Company’s common stock over the 24-month term. In August, 2012, the Initial Purchase Agreement was extended for an additional 24-month term through September 2015. During the three months endedMarch 31, 2014, the Company issued 0.8 million shares of Common Stock under the provisions the Initial Purchase Agreement with Aspire for gross proceeds of approximately $5.6 million. As of March 31, 2014, the full $20.0 million worth of shares of the Company's stock had been issued under the Initial Purchase Agreement (initially Agreement.


1624
Index

months).In March 2014, the Company entered into a new common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital, which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $30.0 million worth of shares of the Company’s common stock over the 24-month term. At the Company’s discretion, it may present Aspire Capital with purchase notices under the Purchase Agreement from time to time to purchase the Company’s Common Stock,common stock, provided certain price and other requirements are met. The purchase price for the shares of stock iswas based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice we submitthe Company submits to Aspire Capital, from time to time, and is based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the Purchase Agreement. The Company and Aspire Capital shall not effect any sales under the Purchase Agreement on any date where the closing sales price is less than 75% of the closing sales price on the business day immediately preceding the date of the Purchase Agreement. The Company’s net proceeds will depend on the purchase price and the frequency of the Company’s sales of shares to Aspire Capital; provided, however, that the maximum aggregate proceeds from sales of shares is $20.0 million. The Company’s delivery of purchase notices will be made subject to market conditions, in light of the Company’s capital needs from time to time and under the limitations contained in the Purchase Agreement. As consideration for entering into the Purchase Agreement, effective September 30, 2011, we issued 99,010are obligated to issue 150,000 shares of our Common Stockcommon stock to Aspire Capital (the “Commitment Shares”). The issuance of shares of common stock to Aspire Capital pursuant to the Purchase Agreement, including the Commitment Shares, and the sale of those shares from time to time by Aspire Capital to the public, are covered by an effective shelf registration statement on Form S-3.

In August 2012, the Company and Aspire entered into an amendment to the Purchase Agreement providing for an extension of the term of the Purchase Agreement until September 30, 2015. Pursuant to the amendment, we agreed to issue to Aspire a five-year warrant to purchase up to 161,290 shares of our common stock at an exercise price of $6.00 per share (the closing price of our common stock on the date the amendment was executed).

During the nine months endedSeptember 30, 2013, the Company issued 1,639,659 shares of Common Stock under the provisions of its equity line of credit with Aspire for gross proceeds of approximately $11.1 million. As of September 30, 2013, the remaining amount available to the Company under the Purchase Agreement was $5.6 million.

In the second quarter of 2013, the Company completed an underwritten offering of 2.0 million shares of the Company's common stock, at a public offering price of $5.00 per share.  The underwriters also exercised their entire over-allotment option of 0.3 million shares.The Company received gross proceeds of $11.5 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company.

Option Exercises

During the ninethree months ended ended September 30, 2013March 31, 2014, option holders exercised an aggregate of 16,36912,800 options at at exercise prices between of $4.905.20 and $5.90$6.20 per share for gross proceeds of approximately $0.1 million.


Warrant Exercises

17
Index


To raise capital on terms that we deemed favorable, during the nine months endedSeptember 30, 2013, the Board authorized certain inducements to warrant holders to exercise outstanding common stock purchase warrants significantly before their expiration dates. The Company determined in each instance that such inducements were modifications of equity instruments, and an incremental fair value of the inducement was determined using the Black-Scholes option pricing model.

During the ninethree months ended ended September 30, 2013March 31, 2014, warrant holders exercised an aggregate of 401,215250,000 warrants at an exercise prices betweenprice of $5.10 and $7.40 per share for gross proceeds of approximately $2.11.3 million. As an inducement to exercise, we paid certain warrant holders $0.30 per share upon each exercise. The incremental fair value of the inducement recorded was $0.
Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the ninethree months ended September 30, 2013March 31, 2014:

Stock Options Warrants Stock Options Warrants
Shares Weighted Average Exercise Price Shares Weighted Average Exercise Price Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (In Thousands) Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 20122,168,668
 $12.85 5,528,761
 $15.65
Outstanding at December 31, 2013 2,932,191
 $11.19
 6.8 $1,658.1
 4,898,266
 $16.50
 2.6 $1,811.0
                
Changes during the Year:    
Changes during the Period:            
Granted895,418
 7.06 42,835
 6.28 1,169,200
 $7.70
   2,722
 $12.26
  
Exercised(16,369) 5.29 (401,215) 5.30 (12,800) $5.58
   (250,000) $5.10
  
Forfeited(86,212) 5.51 —
 — (109,329) $6.97
   (100,108) $70.00
  
Expired(120,837) 16.99 (116,079) 20.61 (66,565) $14.77
   (59,852) $57.76
  
Outstanding at September 30, 20132,840,668
 $11.12 5,054,302
 $16.26
    
Outstanding at March 31, 2014 3,912,697
 $10.22
 7.4 $1,896.7
 4,491,028
 $15.39
 2.4 $1,661.5
Vested at March 31, 2014 or expected to vest in the future 3,596,457
 $10.46
 7.2 $1,848.9
 4,491,028
 $15.39
 2.4 $1,661.5
Vested at March 31, 2014 2,520,755
 $11.50
 6.5 $1,600.9
 4,473,306
 $15.42
 2.3 $1,661.5

During the ninethree months ended September 30, 2013March 31, 2014 and 20122013, the Company issued warrants for services as follows ($ in thousands, except share data):
  Nine Months Ended September 30,
   2013 2012
Number of Common Stock Purchase Warrants Issued 20,407
 38,500
Value of Common Stock Purchase Warrants Issued $70.5
 $166.2



  Three Months Ended March 31,
   2014 2013
Number of Common Stock Purchase Warrants Issued —
 3,913
Value of Common Stock Purchase Warrants Issued $—
 $14.9


Restricted Stock

During the ninethree months ended September 30, 2013March 31, 2014 and 20122013, the Company issued restricted stock for services as follows ($ in thousands, except share data):


17
Index

 Nine Months Ended September 30, Three Months Ended March 31,
 2013 2012 2014 2013
Number of Restricted Stock Issued 452,454
 269,727
 329,698
 177,492
Value of Restricted Stock Issued $2,967.7
 $1,438.6
 $2,511.7
 $1,127.9

The weighted average estimated fair value of restricted stock issued for services in the ninethree months ended September 30, 2013March 31, 2014 and 20122013 was $6.56$7.62 and $5.33$6.35 per share, respectively. The fair value of the restricted stock was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally within one year.


18
Index


Note 1211 – Share-Based Compensation

Share-based Compensation

We utilize share-based compensation in the form of stock options, warrants and restricted stock.  The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2013March 31, 2014 and 20122013 (in thousands):
Three Months Ended September 30, Nine Months Ended September 30, Three Months Ended March 31,
2013 2012 2013 2012 2014 2013
Cost of goods sold$88.8
 $19.8
 $233.7
 $120.1
 $138.1
 $86.4
Research and development319.9
 102.2
 667.0
 362.4
 476.8
 217.4
Selling, general and administrative1,718.9
 1,794.2
 4,511.8
 4,988.7
 3,278.7
 1,914.7
Total share-based compensation expense$2,127.6
 $1,916.2
 $5,412.5
 $5,471.2
 $3,893.6
 $2,218.5
           

Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at September 30, 2013March 31, 2014 were as follows (dollars in thousands):
Stock Options Warrants Restricted StockStock Options Warrants Restricted Stock
Unrecognized compensation cost$3,101.8
 $16.2
 $588.7
$6,490.0
 $46.2
 $208.2
Expected weighted-average period in years of compensation cost to be recognized4.07
 0.24
 0.57
5.62
 1.30
 0.35

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the ninethree months ended September 30, 2013March 31, 2014 and 20122013 were as follows (dollars in thousands):
Stock Options WarrantsStock Options Warrants
Nine Months Ended September 30, Nine Months Ended September 30,Three Months Ended March 31, Three Months Ended March 31,
2013 2012 2013 20122014 2013 2014 2013
Total fair value of shares vested$2,470.0
 $3,637.8
 $123.0
 $121.6
$1,927.4
 $1,305.0
 $8.7
 $43.8
Weighted average estimated fair value of shares granted$4.30
 $3.63
 $3.45
 $4.32
$5.47
 $4.71
 $—
 $3.82


Note 1312 – Income Taxes
 
The Tax Reform ActAs of 1986 enacted a complex setDecember 31, 2013, the Company had approximately $110.6 million of rules limiting the utilization of net operating loss carryforwards (“NOL”)Federal NOLs available to offset future taxable income following a corporate ownership change. Theexpiring from 2025 through 2033. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s ability to utilize its NOL carryforwards isNOLs could be limited followingin the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.  If a change of ownership in excess of fifty percentage points during any three-year period.

Since the year 2000, the Company has had several changes in ownership which has resulted in adid occur there would be an annual limitation on the usage of the Company’s ability to apply net operating losses to future taxable income. Aswhich are available through 2033.

In assessing the realizability of December 31, 2012,deferred tax assets, including the Company has lost $26.0 million or $8.8 million in tax benefits, of net operating losses applicable to Federal income taxes which expired due to these limitations and expiration of net operating loss carryforwards. At December 31, 2012, the Company had net operating loss carryforwards of approximately $69.7 million applicable("NOLs"), the Company assesses the available positive and negative evidence to estimate if sufficient future Federaltaxable income taxes. Thewill be generated to utilize its existing deferred tax loss carryforwards are subject to annual limitations and expire at various dates through 2030. Theassets.  Based on its assessment, the Company has recordedprovided a full valuation allowance against its net deferred tax asset because it is more likely than not that such deferred tax assets will not be realized.as their future utilization remains uncertain at this time.

18
Index


Deferred tax liabilities were $4.14.4 million and $3.64.4 million as of September 30, 2013March 31, 2014 and December 31, 20122013, and relate to the taxable temporary differences on the goodwill recognized in the PCT acquisition in 2011, and the in-process R&D intangible asset recognized in the Amorcyte acquisition in 2011. The taxable temporary difference associated with the goodwill, which is tax deductible and will be amortized over 15 years, will continue to increase the deferred tax liability balance over the amortization period, with an associated charge to the tax provision in each period. The deferred tax liabilities will only reverse when these indefinite-lived assets are sold, impaired, or reclassified from an indefinite-lived asset to a finite-lived asset.


19
Index

As of September 30, 2013March 31, 2014, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.
 

Note 14 – Discontinued Operations
Regenerative Medicine - China segment

In 2009, the Company operated its Regenerative Medicine-China business in the People’s Republic of China (“China” or “PRC”) through its subsidiary, a wholly foreign owned entity (“WFOE”) and entered into contractual arrangements with certain variable interest entities (“VIEs”). Foreign companies have commonly used VIE structures to operate in the PRC, and while such structures are not uncommon, they had drawn greater scrutiny from the local Chinese business community in the PRC who urged the PRC State Council to clamp down on these structures. In addition, in December 2011, China’s Ministry of Health announced its intention to more tightly regulate stem cell clinical trials and stem cell therapeutic treatments in the PRC, which created uncertainty regarding the ultimate regulatory environment in the PRC. Accordingly, the Company took steps to restrict, and ultimately eliminate, its regenerative medicine business in the PRC. As a result of these steps, the Company discontinued its operations in its Regenerative Medicine-China business. The Company determined that any liability arising from the activities of the WFOE and the VIEs will likely be limited to the net assets currently held by each entity. As of March 31, 2012, the Company recognized the following loss on exit of the Regenerative Medicine-China business (in thousands):
Cash$195.1
Prepaid expenses and other current assets14.9
Property, plant and equipment, net1,023.7
Other Assets330.5
Accounts payable(177.1)
Accrued liabilities(79.2)
Accumulated comprehensive income(169.9)
Loss on exit of segment$1,138.0
The operations and cash flows of the Regenerative Medicine - China business were eliminated from ongoing operations as a result of our exit decision, and the Company will not have continuing involvement in this business going forward. The operating results of the Regenerative Medicine – China business for the nine months endedSeptember 30, 2012, which are included in discontinued operations, were as follows (in thousands):
 Nine Months Ended September 30, 2012
Revenue$52.3
Cost of revenues(30.6)
Research and development(103.3)
Selling, general, and administrative(497.3)
Other income (expense)(6.8)
Loss on exit of segment(1,138.0)
Loss from discontinued operations$(1,723.7)


Pharmaceutical Manufacturing - China segment

On November 13, 2012, the Company completed the divestiture (the “Erye Sale”) of our 51% interest (the “Erye Interest”) in Suzhou Erye Pharmaceuticals Company Ltd., a Sino-foreign equity joint venture with limited liability organized under the laws of the PRC primarily engaged in the manufacture of generic antibiotics (“Erye”), to Suzhou Erye Economy & Trading Co., Ltd., a limited liability company organized under the laws of the PRC (“EET”), and Highacheive Holdings Limited, a limited liability

20
Index

company organized under the laws of the British Virgin Islands (“Highacheive” and together with EET, each a “Purchaser” and collectively the “Purchasers”). The Erye Sale was consummated pursuant to the terms and conditions of the Equity Purchase Agreement, dated as of June 18, 2012 (as amended, the “Equity Purchase Agreement”), by and among our Company, China Biopharmaceuticals Holdings, Inc., a wholly-owned subsidiary of NeoStem (“CBH”), EET, Highacheive, Fullbright Finance Limited, a limited liability company organized under the laws of the British Virgin Islands (“Fullbright”), and Erye. Pursuant to the Equity Purchase Agreement, the aggregate purchase price paid to the Company by the Purchasers for the Erye Interest consisted of (i) approximately $12.3 million in cash, (ii) the return to the Company of 104,000 shares of NeoStem common stock and (iii) the cancellation of 117,000 options and 64,000 warrants to purchase our common stock. The fair value of the shares was based on the Company's closing price on the date of sale, and was recorded as Treasury Stock in our balance sheet. The fair values of the canceled options and warrants were based on the Black-Scholes values on the date of sale, and were recorded against Additional Paid in Capital in the accompanying balance sheet.  The Company recognized the following loss on the date of sale of its 51% interest in Erye on November 13, 2012 (in thousands):
Fair value of consideration received$13,397.9
Carrying value of segment non-controlling interest6,015.0
Carrying value of segment accumulated comprehensive income4,387.4
 $23,800.3
Less carrying amount of assets and liabilities sold: 
Cash$8,457.5
Restricted Cash2,918.1
Accounts Receivable6,130.2
Inventories15,077.7
Prepaid expenses and other current assets957.8
Property, plant and equipment, net38,102.0
Other assets5,946.3
Accounts payable(9,604.8)
Accrued liabilities(2,008.8)
Bank loans(15,133.5)
Notes payable(6,599.3)
Other liabilities(9,166.8)
Amount due related party(7,859.7)
 $(27,216.7)
  
Loss on exit of segment$(3,416.4)

The operations and cash flows of the Pharmaceutical Manufacturing - China business were eliminated from ongoing operations with the sale of the Company's Erye Interest. The operating results of the Pharmaceutical Manufacturing - China business for the three and nine months endedSeptember 30, 2012, including the estimated asset impairments based on the definitive agreement purchase price as of September 30, 2012, were as follows (in thousands):

21
Index

 Three Months Ended September 30, 2012 Nine Months Ended September 30, 2012
Revenue$20,036.4
 $57,254.7
Cost of revenues(11,551.5) (37,131.5)
Research and development(611.8) (2,231.5)
Selling, general, and administrative(3,514.7) (9,714.8)
Other expense(0.9) (1,008.3)
Provision for income taxes(1,029.9) (1,535.4)
Asset impairments(3,175.5) (31,170.1)
Loss on sale of segment—
 —
Loss from discontinued operations$152.1
 $(25,536.9)


Note 1513 – Related Party Transactions
 
On November 13, 2012, weIn December 2013, the Company modified both the First Mortgage and our subsidiary, CBH, sold our 51% ownership interest in Erye to Fullbright and EETSecond Mortgage with TD Bank, N.A. (see Note 14)9). EET was priorPursuant to the sale the holderLoan Modifications, Andrew L. Pecora, M.D., Regional Cancer Care Associates LLC (Dr. Pecora’s medical practice), and certain partners in such practice, have been released as guarantors of the minority 49% ownership interest in Erye,Second Mortgage Loan, and wasNeoStem has become a party along with our subsidiary CBHguarantor of the Loans pursuant to a Guaranty of Payment delivered by NeoStem to the Joint Venture Agreement which had governed the ownership of the respective interests in Erye. Fullbright is an affiliate of EET. Mr. Shi Mingsheng (a former member of our Board of Directors,Lender. Dr. Pecora, currently serves as a NeoStem director, NeoStem’s Chief Visionary Officer, PCT’s Chief Medical Officer and Chairman of the Board of Erye) and Madam Zhang Jian (the General Manager of Erye, and formerly our Vice President of Pharmaceutical Operations) are the principal equity holders of each of EET and Fullbright. Fullbright assigned all its rights and obligations under the Equity Purchase Agreement (except for its obligations in respect of the return of certain NeoStem securities held by it as part of the purchase price, and its obligations in respect of closing deliverables) to Highacheive. As a result of the assignment, the Purchasers of our Erye Interest were EET and Highacheive.Amorcyte’s Chief Scientific Officer.


Note 1614 – Commitments and Contingencies
 
Lease Commitments
 
The Company leases offices, of which certain have escalation clauses and renewal options, and also leases equipment under certain noncancelable operating leases that expire from time to time through 2017.2018. In January 2014, the Company signed a new lease for additional space at its current executive offices at 420 Lexington Avenue, New York, NY 10170. The new lease is believed to provide sufficient space for the near future and shall extend through 2018. This property is used as the Company's corporate headquarters.

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of September 30, 2013March 31, 2014 are as follows (in thousands):  
Years ended Operating Leases Operating Leases
2013 $223.1
2014 900.9
 $763.0
2015 726.7
 840.4
2016 568.6
 682.3
2017 294.7
 386.9
2018 5.9
Total minimum lease payments $2,714.0
 $2,678.5
 
Expense incurred under operating leases was approximately $0.30.2 million and $0.40.3 million for the three months ended September 30, 2013March 31, 2014 and 2012, respectively, and $0.9 million and $1.2 million for the nine months endedSeptember 30, 2013 and 2012, respectively.
 
Contingencies
 
Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.

22
Index

In connection with the issuance to investors and service providers of many of the shares of the Company’s common stock and warrants to purchase common stock previously disclosed and described herein, the Company granted the holders registration rights providing for the registration of such shares of common stock and shares of common stock underlying warrants on a registration statement to be filed with the Securities and Exchange Commission (“SEC”) so as to permit the resale of those shares. Certain of the registration rights agreements provided for penalties for failure to file or failure to obtain an effective registration statement. With respect to satisfying its obligations to the holders of these registration rights, the Company has been in various situations. The Company had previously filed a registration statement as required for some of the holders, and in May 2011 filed a registration statement for all of the holders (except for holders whose shares of Common Stock were currently salable under Rule 144 of the Securities Act or who waived certain rights); such registration statement was declared effective by the SEC on September 30, 2011. The Company has certain obligations to maintain the effectiveness of this registration statement. Certain holders who had outstanding registration rights had previously waived their registration rights or were subject to lock-up agreements. No holder has yet asserted any claim against the Company with respect to a failure to satisfy any registration obligations. Were someone to assert a claim against the Company for breach of registration obligations, the Company believes it has several defenses that would result in relieving it from some or any liability, although no assurances can be given. The Company also notes that damage claims may be limited, as (i) most shares of Common Stock as to which registration rights attached are either now registered or currently salable under Rule 144 of the Securities Act or are otherwise currently subject to other restrictions on sale and (ii) the shares of Common Stock underlying warrants with registration rights are now registered, and during much of the relevant periods the warrants with registration rights generally have been out of the money, were subject to lock-up agreements and/or the underlying shares of Common Stock were otherwise subject to restrictions on resale. Accordingly, were holders to assert claims against the Company based on breach of the Company’s obligation to register, the Company believes that the Company’s maximum exposure would not be material.

Note 1715 – Subsequent Events

19
Index

 

Public OfferingCalifornia Stem Cell Acquisition

On October 3, 2013May 8, 2014, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with Aegis Capital Corp. (“Aegis”“Closing”), providing for the offer and sale in a firm commitment underwritten public offeringNeoStem closed its acquisition (the “Offering”“CSC Acquisition”) of 5,000,000 sharesCSC, pursuant to the terms of the Company's common stock, par value $0.001 per share atAgreement and Plan of Merger, dated as of April 11, 2014 (the “Merger Agreement”), by and among NeoStem, CSC, NBS Acquisition Sub I, Inc., a public offering priceDelaware corporation and a wholly-owned subsidiary of $7.00 per share.  The underwriter also exercised its entire over-allotment optionNeoStem (“Subco”), NBS Acquisition Sub II, LLC, a Delaware limited liability company and a wholly-owned subsidiary of 750,000 sharesNeoStem (“Subco II”), and Jason Livingston, solely in accordancehis capacity as CSC stockholder representative (together with his permitted successors, the Underwriting Agreement.The Company received gross proceeds of approximately $40.3 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The Offering closed on October 9, 2013“CSC Representative”).


OptionPursuant to the Merger Agreement, on the Closing Date, (1) Subco was merged with and Warrant Exercisesinto CSC (the “First Merger”) and (2) CSC was then merged with and into Subco II (the “Second Merger”, and collectively with the First Merger, the “Mergers”), with Subco II surviving the Mergers as a wholly-owned subsidiary of NeoStem. At Closing, Subco II changed its legal name to NeoStem Oncology, LLC.

SubsequentCSC (which after the Mergers is known as NeoStem Oncology, LLC) is a biopharmaceutical company with deep expertise in stem cell biology that is engaged in the development of therapies using a patient’s own, i.e., autologous, cells. To date, CSC’s development efforts have been directed at immunotherapies for cancer, regenerative medicine for motor neuron replacement and dermatology. CSC’s most advanced program is an immunotherapy, Melapuldencel-T, which uses patients’ own tumor cells to September 30, 2013maximize the ability of their immune system to identify and eliminate the cancer initiating cells that are capable of reconstituting or developing new tumors (i.e., warrant holders exercised an aggregate“cancer stem cells” or “replicating cells”). The focus of 161,951 warrants at exercise prices between $5.10that program is the treatment of metastatic melanoma. As a result of encouraging Phase 2 data, CSC expects to initiate a Phase 3 clinical trial later in 2014, for which it has received Special Protocol Assessment (“SPA”) and $7.00 per share for gross proceedsFast Track designation, as well as Orphan Drug designation. CSC maintains corporate offices and research facilities in Irvine, California.
Aggregate Merger Consideration

Pursuant to the terms of approximately $0.9 millionthe Merger Agreement, all shares of CSC common stock (“CSC Common Stock”) and CSC preferred stock (“CSC Preferred Stock”, and option holders exercised ancollectively with the CSC Common Stock, the “CSC Capital Stock”) outstanding immediately prior to the Closing, and all outstanding unexercised options to purchase CSC Common Stock (“CSC Options”) (treated as if a net exercise had occurred), were canceled and converted into the right to receive, in the aggregate of 15,000 options at exercise prices between $4.00 and $4.40 per share, for gross proceeds of approximately $0.1 million.(and giving effect to the liquidation preferences accorded to the CSC Preferred Stock):

(1)
An aggregate of 5,329,593 shares of NeoStem common stock (subject to payment of cash in lieu of fractional shares) (the “Closing Merger Consideration”).

(2)If payable after the Closing, certain milestone payments in an amount of up to $90 million in the aggregate, payable in shares of NeoStem common stock or cash, in NeoStem’s sole discretion, in the event of the successful completion of certain milestone events in connection with the CSC business acquired by NeoStem (the “Milestone Payments”, and together with the Closing Merger Consideration, the “Merger Consideration”).





2320
Index

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
 
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Cautionary Note Regarding Forward-Looking Statements” herein and under “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2012.2013. The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this quarterly report and in our annual report on Form 10-K for the year ended December 31, 2012.2013.
 
Overview

NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a leader in the emerging cellular therapy industry. CellularWe are pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. We have multiple cell therapy addressesplatforms that work to address the process by which newpathology of disease using a person's own cells are introduced into a tissueto amplify the body's natural repair mechanisms including enhancing the destruction of cancer initiating cells, repairing and administered to prevent or treat disease, or regeneratereplacing damaged or aged tissue. Modern cell-based therapies have progressed from the first recorded human to human blood transfusion 200 years ago through to the advanced cellular therapies of today including bone marrowtissue, cells and organ transplantation, tissue bankingorgans and reproductive in vitro fertilization and future therapies being investigated to treat cancer, cardiologic, neurologic, ophthalmic and orthopedic diseases among others.restoring their normal function. We anticipatebelieve that cellular therapiescell therapy will haveplay a large role in changing the natural history of diseases as more breakthrough therapies are developed, ultimately lessening the fight against chronicoverall burden of disease on patients and in lesseningtheir families as well as the economic burden that these diseases pose toimpose upon modern society.

Our business model includes the development of novel proprietary cell therapy products, as well as operating a revenue-generating contract development and manufacturing organization (“CDMO”)service business that we leverage for the development of our therapeutics while providing servicesservice to othersother companies in the regenerative medicine industry.cell therapy industry developing products. The combination of aour own therapeutic development business and a revenue-generating service provider business provides the Company with unique capabilities for cost effective in-house product development and immediate revenue and future cash flow generation.to help underwrite our internal development programs. This business model enables the Company to be opportunistic in growing its pipeline as evidenced by the Company's acquisition in May 2014 through the issuance of equity of California Stem Cell, Inc. ("CSC"), a cell biotechnology corporation that is developing cellular immunotherapies for cancer, an area we view to be one of the most promising sub-sectors in biotechnology. CSC, now known as NeoStem Oncology, LLC, is driving the Company's Targeted Immunotherapy Program for cancer through the development of its lead product candidate, Melapuldencel-T, to treat Stage IV or recurrent melanoma. The Phase 3 protocol is the subject of a Special Protocol Assessment (SPA), indicating that the Food and Drug Administration ("FDA") is in agreement with the design, clinical endpoints, and planned clinical analyses of the Phase 3 trial that will serve as the basis for a Biologics License Application ("BLA"). This protocol calls for enrolling 250 patients and is expected to be initiated in 2014.

We are currently developing therapies to address ischemia through our CD34 Cell Program. Ischemia occurs when the supply of oxygenated blood in the body is restricted. We seek to reverse this restriction through the development and formation of new blood vessels. AMR-001 is our most clinically advanced product candidate in our CD34 Cell Program and is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack) ("AMI"). In December 2013, the Company completed enrollment in its PreSERVE AMI study. PreSERVE AMI is a randomized, double-blinded, placebo-controlled Phase 2 clinical trial testing AMR-001, an autologous (donor and recipient are the same) adult stem cell product for the treatment of patients with left ventricular dysfunction following acute ST segment elevation myocardial infarction (STEMI). With the last patient of the planned 160 patient trial infused in late December 2013, we expect the last patient six-month follow-up to occur in June 2014. Once the primary end point six-month data is collected, the data set will be locked and analysis will begin with a submission for a possible presentation of the study at the American Heart Association's Scientific Sessions to be held November 15-19, 2014. If approved by Food and Drug Administration (the "FDA ") and/or other worldwide regulatory agencies following successful completion of further trials, AMR-001 would address a significant medical need for which there is currently no effective treatment, potentially improving longevity and quality of life for those suffering a STEMI, and positioning the Company to capture a meaningful share of this worldwide market. We also expect to advance the technology into other clinical indications such as chronic heart failure ("CHF"), traumatic brain injury ("TBI"), and/or critical limb ischemia ("CLI").

Another platform technology we are developing utilizes T Regulatory Cells ("Tregs") to treat diseases caused by imbalances in an individual's immune system.  In collaborating with Becton-Dickinson and the University of California, San Francisco, we are utilizing this technology platform of our majority-owned subsidiary, Athelos Corporation ("Athelos"), to restore immune balance by enhancing Treg cell number and function.  Tregs are a natural part of the human immune system and regulate the activity of T effector cells, the cells that are responsible for protecting the body from viruses and  other foreign antigen exposure. When Tregs function properly, only harmful foreign materials are attacked by T effector cells. In autoimmune disease it is thought that deficient Treg activity permits the T effector cells to attack the body's own tissues, and in allergic diseases, like asthma, the immune system overreacts to harmless foreign substances. We plan to initiate a Phase 2 study of Treg based therapeutics  to treat

21
Index

type 1 diabetes in 2014. We also plan to initiate a Phase 1 study in Canada of Treg based therapeutics in support of a steroid resistant asthma indication in 2014.

Pre-clinical assets include our VSEL TM (Very Small Embryonic Like) Technology regenerative medicine platform. Regenerative medicine holds the promise of improving clinical outcomes and reducing overall  healthcare costs.  We are working on a Department of Defense funded study of VSELsTM for the treatment of chronic wounds. Other preclinical work with VSELsTM includes exploring macular degeneration as a target indication.

Progenitor Cell Therapy, LLC our("PCT") is a contract manufacturer that generates revenue. This wholly owned subsidiary, (“PCT”),which we acquired in 2011, is a leading CDMOan industry leader in the cellular therapy industry.providing high quality manufacturing capabilities and support to developers of cell-based therapies to enable them to improve efficiencies and profitability and reduce capital investment for their own development activities. Since its inception more than 15 years ago, PCT has provided pre-clinical and clinical current Good Manufacturing Practice (“cGMP”) development and manufacturing services to overmore than 100 clientsclients. PCT has experience advancing regenerative medicine product candidates from product inception through rigorous quality standards all the way through to human testing.testing, BLA filing and FDA product approval. PCT's core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, engineering and innovation services, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. PCT has two cGMP, state-of-the art cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Expansion work currently in progress at PCT's New Jersey and California facilities is expected to be completed during the first quarter of 2014. The Company intends to pursueis pursuing commercial expansion of our manufacturing operations both in the U.S. and internationally. Additionally, with the acquisition of CSC, PCT can leverage CSC's additional manufacturing capacity in Irvine, California as well as the personnel experience and expertise in immunotherapy to provide additional manufacturing and /or development work to advance NeoStem's platform technology as well as technologies of PCT's client base.

Our wholly-owned subsidiary, Amorcyte, LLC (“Amorcyte”), is developing AMR-001 forStrategic acquisitions have been the treatmentcornerstone of cardiovascular disease. AMR-001 represents Amorcyte's most clinically advanced therapeutic product candidateNeoStem’s growth and enrollment for the Phase 2 PreSERVE clinical trialhave been selected in order to investigate AMR-001's safety and efficacy in preserving heart function after a particular type of acute myocardial infarction (“AMI”) commenced in 2012. We are on trackprovide value to complete patient enrollment for this study in 2013 with the first data readout expected six to eight months after the last patient is infused. If approvedstockholders by the U.S. Food and Drug Administration ("FDA") and/or other worldwide regulatory agencies, AMR-001 would address a significant unmet medical need in the treatment of AMI, potentially improving the quality and longevity of life for those afflicted, and positioning the Company to capture a meaningful sharetaking advantage of the worldwide AMIinfrastructure we have created which includes strong development, regulatory and manufacturing expertise. By adding Melapuldencel-T, a late stage novel proprietary cancer cell therapy market. Potential congestive heart failure and traumatic brain injury indicationsinto our pipeline, we look to further advance towards our goal of delivering transformative cell based therapies to the market to help patients suffering from life-threatening medical conditions. Coupled with our best in class manufacturing capability, the stage is set for AMR-001 are also being explored.

Through our majority-owned subsidiary, Athelos Corporation (“Athelos”), we are collaborating with Becton-Dickinson and the University of California, San Francisco in early stageus to realize meaningful clinical development of a therapy that utilizes T-cells,and manufacturing efficiencies, further positioning NeoStem to treat autoimmune and inflammatory conditions. We plan to file an Investigational New Drug Application ("IND") to investigate the clinical feasibility of nTreg-based therapeutics to prevent and/or treat steroid resistant asthma (preparing for Phase 1b/2a trial). Through INDs sponsored by UCSF we also plan to study nTreg-based therapeutics in prevention and/or treatment of type 1 diabetes (Phase 2 IND in preparation), and solid organ transplantation tolerance (Phase 1 IND submitted).

Pre-clinical assets include our VSELTM(Very Small Embryonic Like) Technology platform. We expect to file an IND with the FDA to initiate a National Institutes of Health ("NIH") funded human clinical study to investigate the impact of VSELsTMin a tissue repair application. We are also working on a Department of Defense funded study of VSELsTMfor the treatment of chronic wounds. Other preclinical work with VSELsTMincludes exploring macular degeneration as a target indication.

24
Index


NeoStem's origins are in adult stem cell collection and storage and we believe that as new therapeutics are developed utilizing one's own stored cells (autologous), the market penetration rate for the collection and storage business may rise sharply from its current low single digits percentage level, allowing our developing network to scale rapidly if the demand grows.

In 2011, we operated our business in three reportable segments: (i) Cell Therapy — United States; (ii) Regenerative Medicine — China; and (iii) Pharmaceutical Manufacturing — China. In 2012, we exited our operations in China. Effective March 31, 2012, we no longer operated in the Regenerative Medicine – China reportable segment, which was reported in discontinued operations in 2012 (see Note 14). On November 13, 2012, we completed the sale of our 51% interest in Suzhou Erye, which represented the operations in our Pharmaceutical Manufacturing - China segment, and is also reported in discontinued operations (see Note 14). As a result, we currently operate in a single reporting segment - Cell Therapy, which will focus on CDMO and cell therapy development programs.

We believe that NeoStem is ideally positioned to be an integrated leader inlead the cell therapy industry. We have significant basic research and development capabilities, manufacturing facilities on both the east and west coast of the United States, the support of regulatory and logistical expertise and a talented and experienced clinical team. We believe this expertise will allow us to achieve our mission of becoming the premier cell therapy company.

Results of Operations
 
Three and Nine Months Ended September 30, 2013March 31, 2014 Compared to Three and Nine Months Ended September 30, 2012March 31, 2013
 
Net loss for the three months ended September 30, 2013March 31, 2014 was approximately $9.313.8 million compared to $8.48.9 million for the three months ended September 30, 2012March 31, 2013. Our net losses from continuing operations for the three months endedSeptember 30, 2013 and 2012 were approximately $9.3 million and $8.5 million, respectively. The net income from discontinued operations - net for the three months endedSeptember 30, 2012 were approximately $0.2 million, representing the operations of our former Pharmaceutical Manufacturing - China segment, comprised of our 51% interest in Suzhou Erye, which was sold in the fourth quarter of 2012.

Net loss for the nine months endedSeptember 30, 2013 was approximately $26.8 million compared to $51.0 million for the nine months endedSeptember 30, 2012. Our net losses from continuing operations for the nine months endedSeptember 30, 2013 and 2012 were approximately $26.8 million and $23.8 million, respectively. The net losses from discontinued operations - net for the nine months endedSeptember 30, 2012 were approximately $27.3 million, representing the operations of our former Regenerative Medicine – China segment, which was deconsolidated in the first quarter of 2012, and the operations of our Pharmaceutical Manufacturing - China segment.

Revenues

For the three months ended September 30, 2013March 31, 2014, total revenues were approximately $3.74.1 million compared to $4.42.5 million for the three months ended September 30, 2012March 31, 2013, representing a decreasean increase of $0.71.5 million, or 16%61%. Revenues were comprised of the following (in thousands):
Three Months Ended September 30,Three Months Ended March 31,
2013 20122014 2013
Clinical Services$2,241.0
 $2,921.8
$2,567.0
 $1,365.7
Clinical Services Reimbursables649.9
 928.0
748.0
 362.8
Processing and Storage Services816.0
 577.9
740.6
 795.5
Other—
 6.3
$3,706.9
 $4,434.0
$4,055.6
 $2,523.9

Clinical Services, representing process development and clinical manufacturing services provided by PCT to its various clients, were approximately $2.22.6 million for the three months ended September 30, 2013March 31, 2014 compared to $2.91.4 million for the three months ended September 30, 2012March 31, 2013, representing a decreasean increase of approximately $0.71.2 million or 23%88%. The decreaseincrease was primarily due to $1.60.7 million of lowerhigher process development revenue, such revenue being recognized on a "completed contract" basis, which was partially offset byand $0.90.5 million of higher clinical manufacturing revenue (which is recognized as services are rendered).

22
Index

Overall, there were approximately 50% more Clinical Services active clients as of September 30, 2013March 31, 2014 compared to September 30, 2012March 31, 2013., including five new clinical service contracts initiated during the current quarter.

25
Index


◦
Process Development Revenue - Process development revenues were approximately $0.8 million for the three months endedMarch 31, 2014 compared to $0.1 million for the three months endedMarch 31, 2013. In accordance with our revenue recognition policy, process development revenue is recognized upon contract completion for certain clinical service contracts (i.e., when the services under a particular contract are completed). In other words, there is noThe revenue recognized for process development contracts that have not been completed, regardless of the amount of progress billing or the total amount of revenue that will be recognized upon contract completion. During the three months ended September 30, 2013March 31, 2014, primarily related to the majoritycompletion of a large process development contracts had not been completed, resulting in the deferral of approximately $0.6 million of process development revenue as of September 30, 2013. As a result, only $0.2 million of process development revenue was recognizedcontract during the quarter. Conversely, duringIn the three months endedSeptember 30, 2012, moreprior year period, only minor process development contracts had been completed, resulting in lower revenue recognition. In addition, numerous process development contracts were still in process, including five new contracts initiated during the quarter, resulting in approximately $1.8$1.5 million in of deferred process development revenue recognition.as of March 31, 2014. This revenue will be recognized in future periods upon completion of those contracts. Process development revenue will continue to fluctuate from period to period as a result of our process development revenue recognition policy.

◦
Clinical Manufacturing Revenue - Clinical manufacturing revenues were approximately $2.01.8 million for the three months ended September 30, 2013March 31, 2014, compared to $1.11.2 million for the three months ended September 30, 2012March 31, 2013. The increase is primarily due to an increase in the number of patients our customers have enrolled and treated in clinical trials.


Clinical Services Reimbursables, representing reimbursement of expenses for certain consumables incurred on behalf of our clinical service revenue clients, were approximately $0.60.7 million for the three months ended September 30, 2013March 31, 2014 compared to $0.90.4 million for the three months ended September 30, 2012March 31, 2013, representing a decreasean increase of approximately $0.30.4 million or 30%106%. Our reimbursable revenue decrease was impacted by changes in contractual termsGenerally, clinical services reimbursables correlate with certain clients that shifted clinical service expense reimbursables to a fully absorbed billing rate. Generally,services revenues. In addition, our terms for billing reimbursable expenses do not include a significant mark up in the acquisition cost of such consumables, and as a result, the impact of changes in this revenue category hashave little or no impact on our gross profit and net loss.

Processing and Storage Services, representing revenues from our oncology stem cell processing, cord blood, and adult stem cell processing and banking activities, were approximately $0.7 million for the three months endedMarch 31, 2014 compared to $0.8 million for the three months ended September 30,March 31, 2013 compared to $0.6 million for the three months endedSeptember 30, 2012, representing an increasea decrease of approximately $0.20.1 million or 41%7%. The increasedecrease is primarily attributable to increaseddecreased revenue from our oncology stem cell processing services.
 
For the nine months endedSeptember 30, 2013, total revenues were approximately $10.6 million compared to $11.6 million for the nine months endedSeptember 30, 2012, representing a decrease of $1.0 million, or 9%. Revenues were comprised of the following (in thousands):
 Nine Months Ended September 30,
 2013 2012
Clinical Services$6,720.8
 $6,701.2
Clinical Services Reimbursables1,436.3
 2,881.8
Processing and Storage Services2,433.1
 1,976.8
Other—
 19.0
 $10,590.2
 $11,578.8


Clinical Services were approximately $6.7 million for the nine months endedSeptember 30, 2013 compared to $6.7 million for the nine months endedSeptember 30, 2012, representing no overall change. However, process development revenue decreased approximately $0.9 million, which was offset by approximately $1.0 million of higher clinical manufacturing revenue.

◦
Process Development Revenue - Process development revenues were approximately $2.0 million for the nine months endedSeptember 30, 2013, compared to $2.9 million for the nine months endedSeptember 30, 2012. The decrease is due to fewer process development contracts being completed during the nine months endedSeptember 30, 2013 compared to the prior year period. Process development revenue will continue to fluctuate from period to period as a result of our process development revenue recognition policy.

◦
Clinical Manufacturing Revenue - Clinical manufacturing revenues were approximately $4.6 million for the nine months endedSeptember 30, 2013, compared to $3.7 million for the three months endedSeptember 30, 2012.

26
Index

The increase is primarily due to an increase in the number of patients our customers have enrolledOperating Costs and treated in clinical trials.

Clinical Services Reimbursables were approximately $1.4 million for the nine months endedSeptember 30, 2013 compared to $2.9 million for the nine months endedSeptember 30, 2012, representing a decrease of approximately $1.4 million or 50%. Our reimbursable revenue decrease was impacted by changes in contractual terms with certain clients that shifted clinical service expense reimbursables to a fully absorbed billing rate. Generally, our terms for billing reimbursable expenses do not include significant mark up in the acquisition cost of such consumables, and as a result the impact of changes in this revenue category has little or no impact on our net loss.

Processing and Storage Services were approximately $2.4 million for the nine months endedSeptember 30, 2013 compared to $2.0 million for the nine months endedSeptember 30, 2012, representing an increase of approximately $0.5 million or 23%. The increase is primarily attributable to increased revenue from our oncology stem cell processing service.

CostExpenses of Revenues

For the three months ended September 30,March 31, 2014, operating expenses totaled $17.6 million compared to $11.4 million for the three months endedMarch 31, 2013, total costrepresenting an increase of $6.2 million or 55%. Operating expenses were comprised of the following:

Cost of revenues were approximately $3.03.8 million the three months endedMarch 31, 2014 compared to $3.72.4 million for the three months ended September 30, 2012March 31, 2013, representing a decreasean increase of $0.81.4 million or 21%60%. The decrease isincrease was primarily due to fewer third party process development contracts being completedgreater Clinical Service revenues during the three months endedSeptember 30, 2013, resulting in the net deferral of approximately $0.5 million of costs associated with the contracts.current quarter. Overall, gross profit for the three months ended September 30, 2013March 31, 2014 was $0.70.2 million or 20%6%, compared to gross profit for the three months ended September 30, 2012March 31, 2013 of $0.70.1 million or 15%5%. Gross profit percentages generally will increase as clinical serviceClinical Service revenue increases. However, gross profit percentages will also fluctuate from period to period due to the mix of service and reimbursable revenues and costs, as well as the timing of our revenue recognition under our clinical services revenue recognition policy.

For the nine months endedSeptember 30, 2013, total cost of revenuesResearch and development expenses were approximately $9.6 million compared to $9.4 million for the nine months endedSeptember 30, 2012, representing an increase of $0.2 million or 2%. The increase is primarily due higher operating costs to support more project initiatives during the nine months endedSeptember 30, 2013 compared to the prior year period, as well as the net recognition of approximately $0.6 million of deferred costs associated with process development contracts during the nine months endedSeptember 30, 2013. Overall, gross profit for the nine months endedSeptember 30, 2013 was $1.0 million or 9%, compared to gross profit for the nine months endedSeptember 30, 2012 of $2.1 million or 18%.

Operating Expenses

     For the three months endedSeptember 30, 2013 operating expenses totaled $10.0 million compared to $8.84.8 million for the three months ended September 30, 2012March 31, 2014 compared to $3.2 million for the three months endedMarch 31, 2013, representing an increase of approximately $1.21.6 million, or 50%. Research and development expenses related to AMR-001, including expenses associated with our Phase 2 clinical trial, increased by approximately $0.2 million orfor the 14%three months endedMarch 31, 2014. Operating compared to the prior year period. The Phase 2 clinical trial completed enrollment in the fourth quarter of 2013. Research and development expenses associated with our Regulatory T cell (“Treg”) platform increased by approximately $1.0 million, and was primarily due to our efforts to develop Tregs for the treatment of type 1 diabetes, steroid resistant asthma, and organ transplant rejection. We continue to focus efforts on initiating a Phase 2 in type 1 diabetes in 2014 within the Treg platform. Research and development associated with engineering and innovation initiatives at PCT to improve scale up, automation, and integration capabilities also increased during the current quarter compared to the prior year quarter. Equity-based compensation included in research and development expenses for the three months endedMarch 31, 2014 and March 31, 2013were comprised of the following:approximately $0.5 million and $0.2 million, respectively.

23
•
Research and development expenses were approximately $4.5 million for the three months endedSeptember 30, 2013 compared to $2.8 million for the three months endedSeptember 30, 2012, representing an increase of approximately $1.7 million, or 59%. Research and development expenses associated with our Phase 2 clinical trial for AMR-001 increased by approximately $0.4 million for the three months endedSeptember 30, 2013 compared to the prior year period. The trial was initiated in January 2012 and is expected to complete enrollment in the second half of 2013. Research and development expenses associated with our human Regulatory T cell (“Treg”) platform increased by approximately $0.8 million, and was primarily due to the licensing of patents and collaboration with the third parties to develop Tregs for the treatment of type 1 diabetes, steroid resistant asthma, and organ transplant rejection. Research and development associated with our VSELTMTechnology platform, patent-related costs, and engineering and innovation initiatives at PCT to improve scale up, automation, and integration capabilities also increased. Equity-based compensation included in research and development expenses for the three months endedSeptember 30, 2013 and September 30, 2012 were approximately $0.3 million and $0.1 million, respectively.
Index


Selling, general and administrative expenses were approximately $5.69.0 million for the three months ended September 30, 2013March 31, 2014 compared to $5.95.8 million for the three months ended September 30, 2012March 31, 2013, representing a decreasean increase of approximately $0.33.2 million, or 7%55%. Equity-based compensation included in selling, general and administrative expenses for the three months ended September 30, 2013March 31, 2014 was approximately $1.73.3 million, compared to approximately $1.81.9 million for the three months ended September 30, 2012March 31, 2013, representing a decreasean increase of $0.11.4 million. The increase in equity-based compensation is due to the broader use of equity-based compensation during the current quarter, as well as changes in option vesting provisions initiated in 2013, impacting the timing of equity-based compensation expense recognition. Equity-based compensation expense is expected to be lower in future quarters. Non-equity-based general and administrative expenses for the three months ended September 30, 2013March 31, 2014 were approximately $3.85.7 million, compared to approximately $4.13.8 million for the three months ended September 30, 2012, representing a decrease of $0.3 million.

27
Index


For the nine months endedSeptember 30,March 31, 2013 operating expenses totaled $27.3 million compared to $24.6 million for the nine months endedSeptember 30, 2012, representing an increase of $2.7 million or 11%. Operating expenses were comprised of the following:
•
Research and development expenses were approximately $11.6 million for the nine months endedSeptember 30, 2013 compared to $7.5 million for the nine months endedSeptember 30, 2012, representing an increase of approximately $4.1 million, or 55%. Research and development expenses associated with our Phase 2 clinical trial for AMR-001 increased by approximately $2.7 million for the nine months endedSeptember 30, 2013 compared to the prior year period. Research and development expenses associated with our Treg platform increased by approximately $0.4 million compared to the prior year period. Research and development associated with our VSELTMTechnology platform, patent-related costs, and engineering and innovation initiatives at PCT to improve scale up, automation, and integration capabilities also increased. Equity-based compensation included in research and development expenses for the nine months endedSeptember 30, 2013 and September 30, 2012 were approximately $0.7 million and $0.4 million, respectively.

Selling, general and administrative expenses were approximately $15.7 million for the nine months endedSeptember 30, 2013 compared to $17.1 million for the nine months endedSeptember 30, 2012, representing a decrease of approximately $1.4 million, or 8%. Equity-based compensation included in selling, general and administrative expenses for the nine months endedSeptember 30, 2013 was approximately $4.5 million, compared to approximately $5.0 million for the nine months endedSeptember 30, 2012, representing a decrease of $0.51.9 million. Non-equity-based generalThe increase was related to higher strategic and administrative expenses forcorporate development activities, including efforts associated with the nine months endedSeptember 30, 2013 were approximately $11.0 million, comparedacquisition of California Stem Cell, Inc. in the second quarter of 2014, as well as increased corporate infrastructure to approximately $11.6 million for the nine months endedSeptember 30, 2012, representing a decrease of $0.6 million. Selling expenses also decreased $0.4 million compared to the prior year period.support our expanded research and development operations.

Historically, to minimize our use of cash, we have used a variety of equity and equity-linked instruments to compensate employees, consultants and other service providers. The use of these instruments has resulted in charges to the results of operations, which has from time to timebeen significant in the past been significant.past. In general, these equity and equity-linked instruments were used to pay for employee and consultant compensation, director fees, marketing services, investor relations and other activities.


Other Income (Expense)
 
Other expense, net for the three months endedMarch 31, 2014 was approximately $190,000, and other income, net, for the three months ended September 30,March 31, 2013 was approximately $180,00011,000. Other income (expense), and other expense, net for the three months ended September 30, 2012March 31, 2014 was $75,000. Other income for the nine months endedSeptember 30, 2013 and September 30, 2012 was approximately $248,000 and $37,000, respectively. Other income (expense), net primarily relates to the revaluationincrease in the estimated fair value of derivative liabilities that have been established in connectionour contingent consideration liability associated with potential earn out payments on the net sales of our formerly outstanding Convertible Redeemable Series E Preferred Stockproduct candidate AMR-001 (in the event of and following the warrants issued in connection therewith.date of first commercial sale of AMR-001).

For the three months ended September 30, 2013March 31, 2014 interest expense was $0.1 million94,000 compared with $0.4 million44,000 for the three months ended September 30, 2012March 31, 2013. For the nine months endedSeptember 30, 2013 interest expense was $0.2 million compared with $1.4 million for the nine months endedSeptember 30, 2012. Interest expense in the prior year period was primarily due to the amortization of debt discount related to the Series E Preferred Stock, which was fully redeemed in October 2012.
 

Provision for Income Taxes
 
The provision for income taxes for the three and nine months ended September 30, 2013March 31, 2014 relate to the taxable temporary differences on the goodwill recognized in the PCT acquisition in 2011, which is being amortized over 15 years for tax purposes. A tax provision will continue to be recognized each period over the amortization period, and will only reverse when the goodwill is eliminated through a sale, impairment, or reclassification from an indefinite-lived asset to a finite-lived asset.
 
    
Discontinued Operations
Regenerative Medicine - China segment

In 2009, we operated our Regenerative Medicine-China business in the People’s Republic of China (“China” or “PRC”) through our subsidiary, a wholly foreign owned entity (“WFOE”) and entered into contractual arrangements with certain variable

28
Index

interest entities (“VIEs”). Foreign companies have commonly used VIE structures to operate in the PRC, and while such structures are not uncommon, they had drawn greater scrutiny from the local Chinese business community in the PRC who urged the PRC State Council to restrict the use of these structures. In addition, in December 2011, China’s Ministry of Health announced its intention to more tightly regulate stem cell clinical trials and stem cell therapeutic treatments in the PRC, which created uncertainty regarding the ultimate regulatory environment in the PRC. Accordingly, we took steps to restrict, and ultimately eliminate our regenerative medicine business in the PRC. As a result of these steps, we discontinued our operations in our Regenerative Medicine-China business. We determined that any liability arising from the activities of the WFOE and the VIEs will likely be limited to the net assets currently held by each entity.

The operations and cash flows for the Regenerative Medicine - China business for the three months ended March 31, 2012 were reported in discontinued operations. For the three months ended March 31, 2012, the loss from discontinued operations was $1.7 million, and included a $1.1 million loss on exit of segment.

Pharmaceutical Manufacturing - China segment

On November 13, 2012, we completed the divestiture (the “Erye Sale”) of our 51% interest (the “Erye Interest”) in Suzhou Erye Pharmaceuticals Company Ltd., a Sino-foreign equity joint venture with limited liability organized under the laws of the PRC primarily engaged in the manufacture of generic antibiotics (“Erye”), to Suzhou Erye Economy & Trading Co., Ltd., a limited liability company organized under the laws of the PRC (“EET”), and Highacheive Holdings Limited, a limited liability company organized under the laws of the British Virgin Islands (“Highacheive” and together with EET, each a “Purchaser” and collectively the “Purchasers”). The Erye Sale was consummated pursuant to the terms and conditions of the Equity Purchase Agreement, dated as of June 18, 2012 (as amended, the “Equity Purchase Agreement”), by and among NeoStem, China Biopharmaceuticals Holdings, Inc., a wholly-owned subsidiary of NeoStem (“CBH”), EET, Highacheive, Fullbright Finance Limited, a limited liability company organized under the laws of the British Virgin Islands (“Fullbright”), and Erye. Pursuant to the Equity Purchase Agreement, the aggregate purchase price paid to us by the Purchasers for the Erye Interest consisted of (i) $12.3 million in cash, (ii) the return to us of 104,000 shares of NeoStem common stock and (iii) the cancellation of 117,000 options and 64,000 warrants to purchase our common stock. The fair value of the shares was based on our closing price on the date of sale, and was recorded as Treasury Stock in our balance sheet. The fair values of the canceled options and warrants were based on the Black-Scholes values on the date of sale, and were recorded against Additional Paid in Capital in the accompanying balance sheet.  This transaction resulted in a loss on exit of segment of $3.4 million, which was recorded in the fourth quarter of 2012.

The operations and cash flows of the Pharmaceutical Manufacturing - China business were eliminated from ongoing operations with the sale of the Company's 51% interest in Erye. The operating results of the Pharmaceutical Manufacturing - China business for the three and nine months endedSeptember 30, 2012 were classified as discontinued operations. For the three and nine months endedSeptember 30, 2012, net loss from discontinued operations were $0.2 million and $25.5 million, respectively.

Noncontrolling Interests

In connection with accounting for our 51% interest in Erye, which is reported in discontinued operations, we account for the 49% minority shareholder share of Erye's net income or loss with a charge to Noncontrolling Interests. For the three months endedSeptember 30, 2012, Erye's minority shareholders' share of net loss totaled approximately $0.1 million. For the nine months endedSeptember 30, 2012, Erye's minority shareholders' share of net loss totaled approximately $12.5 million. On November 13, 2012, we completed the divestiture of our 51% interest in Erye.

In March 2011, we acquired rights to use patents under licenses from Becton, Dickinson and Company ("BD") in exchange for a 19.9% interest in our Athelos subsidiary. Pursuant to the Stock Purchase Agreement signed in March 2011, BD's ownership will be diluted based on new investment in Athelos (subject to certain anti-dilution provisions). As of September 30, 2013March 31, 2014, BD's ownership interest in Athelos was decreased to 16.7%10.0%, and our ownership increased to 83.3%90.0%. For the three months ended September 30, 2013March 31, 2014 and 20122013, Becton’s minority shareholder’sBD’s share of Athelos’ net loss totaled approximately $0.20.1 million and $0.1 million, respectively. For the nine months endedSeptember 30, 2013 and 2012, Becton’s minority shareholder’s share of Athelos’ net loss totaled approximately $0.3 million and $0.2 million, respectively.

Preferred Dividends
The formerly outstanding Convertible Redeemable Series E Preferred Stock called for annual dividends of 7% based on the stated value of the preferred stock. We recorded dividends of approximately $0.1 million and $0.3 million for the three and nine months endedSeptember 30, 2012. The Series E Preferred Stock was fully redeemed in October 2012.

29
Index


Analysis of Liquidity and Capital Resources
 
At September 30, 2013March 31, 2014 we had a cash balance of approximately $16.941.4 million, working capital of approximately $10.337.8 million, and shareholders’stockholders’ equity of approximately $35.759.6 million.
 
During the ninethree months ended September 30, 2013March 31, 2014, we met our immediate cash requirements through revenue generated from our PCT operations, existing cash balances, the completion of an underwritten common stock offering (which raised an aggregate of $11.5 million, before deducting underwriting discounts and commissions and offering expenses payable by us), the issuance of common stock under the provisions of our equity line of creditpurchase agreement with Aspire, (which raised an aggregate of approximately $11.1 million),and warrant exercises (which raised approximately $2.1 million), and the use ofexercises. Additionally, we used equity and equity-linked instruments to pay for services and compensation.
 

24
Index

Net cash provided by or used in operating, financinginvesting and investingfinancing activities from continuing operations were as follows (in thousands): 
 Nine Months Ended September 30,
 2013 2012
Net cash used in operating activities - continuing operations$(19,737.7) $(16,395.8)
Net cash (used in) provided by investing activities - continuing operations(948.6) 2,530.4
Net cash provided by financing activities - continuing operations23,895.1
 15,620.9
 Three Months Ended March 31,
 2014 2013
Net cash used in operating activities$(11,253.5) $(7,135.7)
Net cash used in investing activities(1,239.6) (53.6)
Net cash provided by financing activities7,719.0
 2,705.4
 
Operating Activities - Continuing Operations
 
Our cash used in operating activities - continuing operations in the ninethree months ended September 30, 2013March 31, 2014 totaled approximately $19.7$11.3 million,, which is the sum of (i) our net loss from continuing operations of $26.813.8 million, and adjusted for non-cash expenses totaling $6.94.6 million (which includes adjustments for equity-based compensation and depreciation and amortization), and (ii) changes in operating assets and liabilities providing approximately $0.12.0 million.

Our cash used in operating activities - continuing operations in the ninethree months ended September 30, 2012March 31, 2013 totaled approximately $16.47.1 million, which is the sum of (i) our net loss from continuing operations of $23.88.9 million, and adjusted for non-cash expenses totaling $8.12.8 million (which includes adjustments for equity-based compensation and depreciation and amortization), and (ii) changes in operating assets and liabilities providing approximately $0.81.0 million.

 
Investing Activities - Continuing Operations
 
During the ninethree months ended September 30, 2013March 31, 2014, we spent approximately $0.91.2 million for property and equipment. During the ninethree months ended September 30, 2012March 31, 2013, we spent approximately $0.20.1 million for property and equipment. In addition, during the nine months endedSeptember 30, 2012, we received advance sale proceeds of approximately $2.7 million from the divestiture of Erye.

 
Financing Activities - Continuing Operations

During the ninethree months ended September 30, 2013March 31, 2014, our financing activities consisted of the following: 
We raised $11.5 million (or $10.5 million in net proceeds after deducting underwriting discounts and commissions and offering expenses) through an underwritten offering of 2.3 million shares of our common stock at a public offering price of $5.00 per share.
We raised gross proceeds of approximately $11.1$5.6 million through the issuance of approximately 1.60.8 million shares of Common Stock under the provisions of our equity line of credit with Aspire.
We raised approximately $0.1 million from the exercise of 16,36912,800 options.
We raised approximately $2.11.3 million from the exercise of 401,215250,000 warrants.
During the three months endedMarch 31, 2013, our financing activities consisted of the following: 
We raised gross proceeds of approximately $2.8 million through the issuance of 454,300 shares of Common Stock under the provisions of our equity line of credit with Aspire.
We raised approximately $0.1 million from the exercise of approximately 20,800 warrants. To induce the exercise of certain of these warrants, we provided consideration to the warrant holders in the form of cash.

30
Index

During the nine months endedSeptember 30, 2012, our financing activities consisted of the following: 
We raised $6.8 million (or $6.0 million in net proceeds after deducting underwriting discounts and offering expenses) through an underwritten offering of 1.7 million units, each unit consisting of one share of common stock and a five year warrant to purchase one share of common stock at an exercise price of $5.10 per share.
We raised an aggregate of approximately $6.1 million in private placements through the issuance of 1.2 million shares of common stock, and 0.8 million five year warrants at exercise prices ranging from $5.10 to $7.40.
We raised an aggregate of approximately $5.9 million from the exercise of approximately 1.0 million warrants. To induce the exercise of certain of these warrants, we provided consideration to the warrant holders in the form of either cash, stock or additional warrants.
We paid $2.3 million in cash for principal and dividend payments of our Convertible Redeemable Series E Preferred Stock.
Liquidity and Capital Requirements Outlook

Capital Requirements
We expect to incur substantial additional costs in connection with our cell therapy development initiatives. In particular, Amorcyte is currently enrolling patients at clinical trial sites for its Phase 2 clinical trial for Amorcyte’s lead product candidate, AMR-001, for the treatment of acute myocardial infarction ("AMI"). The trial began enrollment in January 2012, and is expected to cost approximately $19 million over the first two years and anticipated to cost up to approximately $27 million over a five year period, inclusive of internal manufacturing and project management costs. We have incurred approximately $15.6 million on the Phase 2 trial through September 30, 2013. We are on track to complete enrollment for this study in 2013 with the first data readout expected six to eight months after the last patient is infused. As of November 6, 2013, of the 160 patients required for the trial, 147 have been infused.
Liquidity

We anticipate requiring additional capital for strategic transactions and otherwise in order to (i) fund the development of advanced cell therapies, includingtherapy product candidates, particularly in our Targeted Immunotherapy Program, CD34 Cell Program and T Regulatory Cell Program. The most significant funding needs are anticipated to be in connection with the developmentconduct of AMR-001our Phase 3 clinical trial of Melapuldencel-T for stage IV and recurrent stage III melanoma which is expected to be initiated in 2014 and cost approximately $25 million, and other costs related to the operation of CSC (now known as NeoStem Oncology, LLC), which we acquired in May 2014. The recent acquisition of the CSC operations could result in our Treg program, and (ii)re-prioritizing the timing of the initiation of certain of our other earlier stage clinical trials. We also anticipate requiring additional capital to grow the PCT business, including implementing additional automation capabilities and pursuing plans to establish commercial capacity and expand into Europe.internationally. Additionally, we are currently engagedrecently completed expansion in a build out of each of our MountainView, California andthe Allendale, New Jersey facilities to include up to fivefacility adding laboratory, clean room suites and support facil

25
Index

ities and we commenced construction at the Mountain View facility and expanded its manufacturing capacity with additional clean rooms, laboratory space and support facilities and the build-out is expected to be completed in order to expand capacity.May 2014.

On October 3, 2013, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with Aegis Capital Corp. (“Aegis”), providing for the offer and sale in a firm commitment underwritten public offering (the “Offering”) of 5,000,000 shares of the Company's common stock, par value $0.001 per share at a public offering price of $7.00 per share.  The underwriter also exercised its entire over-allotment option of 750,000 shares in accordance with the Underwriting Agreement.The Company received gross proceeds of $40.3 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The Offering closed on October 9, 2013.


To meet our short and long term liquidity needs, we currently expect to use existing cash balances, (including $40.3 million in gross proceeds raised in October 2013 through an underwritten public offering), our revenue generating activities, and a variety of other means. Those other means include the continued use of our current equity line of credita common stock purchase agreement with Aspire which as of September 30, 2013, had(the "Aspire Agreement"). We entered into a remaining amount available to the Company of $5.6new $30 million. common stock purchase agreement with Aspire in March 2014. Other sources of liquidity could include potential additional warrant exercises, option exercises, issuances of other debt or equity securities in public or private financings, additional warrant exercises, option exercises, and/or sale of assets. In addition, we will continue to seek as appropriate grants for scientific and clinical studies from the National Institutes of Health, Department of Defense, and other governmental agencies and foundations, but there can be no assurance that we will be successful in qualifying for or obtaining such grants. Our history of operating losses and liquidity challenges, may make it difficult for us to raise capital on acceptable terms or at all. The demand for the equity and debt of small cap biopharmaceutical companies like ours is dependent upon many factors, including the general state of the financial markets. During times of extreme market volatility, capital may not be available on favorable terms, if at all. Our inability to obtain such additional capital could materially and adversely affect our business operations.

31
Index

In August 2011, We believe that our current cash balances and revenue generating activities, along with access to the Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP) ofAspire Agreement, will be sufficient to fund the Office of the Congressionally Directed Medical Research Programs (CDMRP) awarded NeoStem approximately $1.78 million to be applied towards funding the Company's VSEL ™ Technology, which award supports an investigation of a unique stem cell population, Very Small Embryonic-Like (VSEL) stem cells, for its bone building and regenerative effects in the treatment of osteoporosis. In 2012, a new level of achievement for VSELTM Technology was realizedbusiness, as we received a two year grant totaling approximately $1.2 million for “Repair of Bone Defects with Human Autologous Pluripotent Very Small Embryonic-Like Stem Cells (VSEL)” from the National Institute of Dental and Craniofacial Research (NIDCR), a division of the National Institutes of Health (NIH). This peer-reviewed grant is to support the first NIH approved clinical study of VSELsin humans for which we expect to file an IND with the FDA in late 2013 or early 2014.  InMarch 2013, we received notice of an award of $300,000 from the National Institute of Allergy and Infectious Diseases (NIAID), a division of NIH, to support year two of the research investigating the use of VSELs for the treatment of acute radiation exposure; approximately $295,000 was previously awarded to support year one of the research. In September 2013, we received notice of an award of approximately $148,000 from the NIH to support research investigating the use of VSELs for the treatment of scleroderma.now operated, into 2015.

While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available or on acceptable terms, if at all, and our negotiating position in capital generating efforts may worsen as existing resources are used. Additional equity financing may be dilutive to our stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict our ability to operate as a business, our stock price may not reach levels necessary to induce option or warrant exercises, and asset sales may not be possible on terms we consider acceptable. If we are unable to raise the funds necessary to meet our long-term liquidity needs, we may have to delay or discontinue the acquisition and development of cell therapies, and/or the expansion of our business or raise funds on terms that we currently consider unfavorable.



Commitments and Contingencies
 
The following table summarizes our obligations to make future payments under current contracts as of September 30, 2013March 31, 2014 (in thousands):
Total Less than 1 Year 1-3 Years 3-5 Years More than 5 YearsTotal Less than 1 Year 1-3 Years 3-5 Years More than 5 Years
Contractual Obligations                  
Mortgages Payable$3,288.1
 $210.2
 $456.1
 $2,320.1
 $301.7
$3,184.0
 $216
 $468.7
 $2,254.3
 $245
Notes Payable751.1
 402.8
 345.5
 2.8
 —
1,707.1
 836.2
 870.9
 —
 —
Operating Lease Obligations2,714.0
 897.7
 1,379.1
 437.2
 —
2,678.5
 1,017.7
 1,438.3
 222.5
 —
$6,753.2
 $1,510.7
 $2,180.7
 $2,760.1
 $301.7
$7,569.6
 $2,069.9
 $2,777.9
 $2,476.8
 $245.0

Under an agreementour agreements with an external clinical research organizationorganizations (“CRO”CRO's”), we will incur expenses relating to our AMR-001 Phase 2 clinical trialtrials for the treatment of AMI.our therapeutic product candidates in development. The timing and amount of these disbursementsexpenses are based on the achievement of certain milestones, patient enrollment, services rendered or as expenses are incurred by the CROperformance, and therefore, we cannot reasonably estimate the timing of these payments.
 
SEASONALITY
 
NeoStem does not believe that its operations are seasonal in nature.
 
OFF-BALANCE SHEET ARRANGEMENTS
 
NeoStem does not have any off-balance sheet arrangements.
 
CRITICAL ACCOUNTING POLICIES AND ESTIMATES

There have been no material changes in our critical accounting policies and estimates during the ninethree months ended September 30, 2013March 31, 2014, compared to those reported in our 20122013 Form 10-K.


26
Index

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.Market risk is the risk of change in fair value of a financial instrument due to changes in interest rates, equity prices, creditworthiness, financing, exchange rates or other factors. Our primary market risk exposure relates to changes in interest rates. However, as of March 31, 2014, we held no investments or marketable securities, and our mortgage, representing our largest component of debt, has a fixed interest rate until 2017, and is not subject to interest rate exposure. As a result, we have no material exposure to market risk related to interest rate changes as of March 31, 2014.

ITEM 4.  CONTROLS AND PROCEDURES.  


32
Index

(a)  Disclosure Controls and Procedures

Disclosure controls and procedures are the Company’s controls and other procedures that are designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that the Company files under the Exchange Act is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met.

As of September 30, 2013March 31, 2014, the Company carried out an evaluation, with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures pursuant to Rule 13a-1513a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective, at the reasonable assurance level, in ensuring that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

(b)  Changes in Internal Control over Financial Reporting

There have been no changes in the Company’s internal controls over financial reporting, as such term is defined in Exchange Act Rule 13a-15, that occurred during the Company’s last quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting, as described below.reporting.
Transition to new stock plan financial reporting system: Effective July 1, 2013, the Company migrated to a new stock plan financial reporting system for the Company’s equity-based compensation expense. This initiative broadened our existing equity-based compensation reporting capabilities, and further integrated our equity-based award administration procedures.

3327
Index

PART II

OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.
There are no material changes to the disclosures provided in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.2013.


ITEM 1A. RISK FACTORS

There have been no material changes from the risk factors previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2012.2013. See the risk factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 20122013 under the caption "Item 1 A - Risk Factors." The CSC Acquisition and the ongoing operations of our NeoStem Oncology, LLC (see Note 15, Subsequent Events, to the interim financial statements) will subject the combined company to additional risks.  Our Current Report on Form 8-K to be filed on the date hereof reporting the closing of the CSC Acquisition will contain a discussion of the risk factors related to the CSC Acquisition and our NeoStem Oncology, LLC subsidiary.

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

As previously disclosed, and as follows:
The Company has agreed to issue equity to certain consultants for services. Effective August 1, 2013March 17, 2014 pursuant to a sixthree month consulting agreement for consulting services in financial and investor communicationsrelations and other specified matters, the Company agreed to issue to a consultant 18,0007,500 shares of the Company's restricted common stock, vesting as to one third2,500 shares on each of April 2, 2014, May 1, 2014 and June 15, 2014. Effective April 1, 2014, pursuant a five month agreement for consulting services in financial advisory and investment banking services and other specified matters, the effective date, the last dayCompany agreed to issue to a consultant 19,500 shares of the third month ofCompany's restricted common stock, vesting as to half two months after the effective date and half on the last day of the term. Effective SeptemberAlso effective April 1, 2013,2014, pursuant to a three month extension for consulting services in information technology and accounting systems, the Company agreed to issue to a consultant, 3,300 shares of the Company's restricted common stock, vesting ratably throughout the term of the agreement on a monthly basis. Also effective April 1, 2014, pursuant to a three month extension for consulting services in accounting systems and regulatory compliance, the Company agreed to issue to a consultant, 2,200 shares of the Company's restricted common stock vesting ratably throughout the term of the agreement on a monthly basis. Also effective April 1, 2014 pursuant to a four month agreement for consulting services in investor relations and other specified matters, the Company agreed to issue to a consultant 20,00012,000 shares of the Company's restricted common stock, vesting as to 5,0003,000 shares aton the endlast day of each month throughout the term of the agreement. Also effective SeptemberEffective April 9, 2014, pursuant to a three month agreement for consulting services in investor relations, developing implementing and planning presentations to the financial community, and other specified matters, the Company agreed to issue to a consultant 10,000 shares of the Company's restricted common stock, vesting ratably throughout the term of the agreement.  Effective May 1, 2013,2014 pursuant to a four month extension for consulting services in strategic planning and tactical application of those services and other specified matters, the Company agreed to issue to a consultant 16,000 shares of restricted common stock vesting as to 50% on the effective date and 50% at the end of the term. Also effective September 1, 2013 pursuant to a six month extension for consulting services in investor relations and other specified matters, the Company agreed to issue to consultant 36,000 shares of the Company's restricted common stock, vesting ratably throughout the term of the agreement on a monthly basis. Effective September 17, 2013, pursuant to a one year extension for consulting services assisting the Company with regard to funding from federal and state agencies,and other specified matters, the Company agreed to issue to a consultant 9,000 shares of the Company's restricted common stock, vesting as to 3,000 shares upon execution, 3,000 shares on October 31, 2013 and 3,000 shares on December 31, 2013.  Effective October 17, 2013, pursuant to a two year amendment to a consulting agreement for advisory services in connection with Amorcyte’s Phase 2 Clinical Trial for AMR-001, the Company agreed to issue a four year warrant (the “Warrant”) to purchase up to 20,000 shares of restricted Common Stock (the "Warrant Shares") at $7.05 per share (the closing price of the Common Stock on October 17, 2013, the Commencement Date), to vest over the term of the agreement as to 2,500 Warrant Shares on October 17, 2013 and each third monthly anniversary of the Commencement Date through and including July 17, 2015. Effective November 1, 2013, pursuant to a five month agreement for consulting services in financial and investor relations and other specified matters, the Company agreed to issue to consultant 20,000 shares of the Company's restricted common stock, vesting ratably throughout the term of the agreement on a monthly basis.
The offer and sale by the Company of the securities described above were made in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), for transactions by an issuer not involving a public offering. The offer and sale of such securities were made without general solicitation or advertising to “accredited investors” as such term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act and/or pursuant to Regulation D or Regulation S, each promulgated under the Securities Act and may not be resold in the United States or to U.S. persons unless registered under the Securities Act or pursuant to an exemption from registration under the Securities Act.
On May 8, 2014, pursuant to the Company's acquisition of CSC, the Company issued an aggregate of 5,329,593 shares of the Company's restricted common stock. The offer and sale of the shares of NeoStem common stock to be issued pursuant to the merger agreement have been made in a private placement in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), for transactions by an issuer not involving a public offering, and/or Regulation D under the Securities Act.


28
Index


ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFTEY DISCLOSURES.


34
Index

Not applicable.

ITEM 5. OTHER INFORMATION.
    
None.On May 8, 2014, NeoStem closed its acquisition of CSC (see footnote 15).



3529
Index

ITEM 6. EXHIBITS
The exhibits to this Form 10-Q are listed in the Exhibit Index included elsewhere herein.


NEOSTEM, INC.
FORM 10Q

Exhibit Index


3.12.1
AmendedAgreement and Restated CertificatePlan of IncorporationMerger, dated as of April 11, 2014, by and among NeoStem, Inc., filed with the Secretary of State of the State of Delaware on October 3, 2013 (filedCalifornia Stem Cell, Inc., NBS Acquisition Company I, Inc., NBS Acquisition Company II, LLC, and Jason Livingston, solely in his capacity as CSC stockholder representative (incorporated by reference to Exhibit 3.14.18 to the Company's Current Report on Form 8-K filed on April 14, 2014)
4.1Registration Rights Agreement, dated October 3, 2013)as of March 11, 2014, by and between NeoStem, Inc. and Aspire Capital Fund, LLC.(incorporated by reference to Exhibit 4.18 to the Company's Annual Report on Form 10-K filed on March 13, 2014).

31.1Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
32.2Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
10.1Common Stock Purchase Agreement, dated as of March 11, 2014, by and between NeoStem, Inc. and Aspire Capital Fund, LLC. (incorporated by reference to Exhibit 10.10 to the Company's Annual Report on Form 10-K filed on March 13, 2014).
10.2Letter Agreement dated July 12, 2013,March 11, 2014 to Employment Agreement dated May 26, 2006 between NeoStem, Inc. and Dr. Robin L. Smith (incorporated by reference to Exhibit 10.49 to the Company's Annual Report on Form 10-K filed on March 13, 2014).
10.3Letter Agreement, dated March 11, 2014, between NeoStem, Inc. and Catherine M. Vaczy, Esq. (incorporated by reference to Exhibit 10.110.57 to the Company’s CurrentCompany's Annual Report on Form 8-K dated July 12, 2013).
10.2Employment Agreement, dated as of July 15, 2013, by and between NeoStem, Inc. and Stephen W. Potter (incorporated by reference to Exhibit 10.1 to the Company’s Current Report10-K filed on Form 8-K dated July 15, 2013).
10.3Employment Agreement, dated as of July 23, 2013 and effective August 5, 2013, by and between NeoStem, Inc., and Douglas W. Losordo, M.D. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K dated August 5, 2013)March 13, 2014).
10.4AmendmentFourth Lease Modification and Additional Space Agreement, dated July 31, 2013 and effective August 5, 2013, by and among Andrew L. Pecora, M.D., FACP, NeoStem, Inc., Progenitor Cell Therapy,January 24, 2014, between SLG Graybar Mesne Lease LLC and Amorcyte, LLC (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K dated August 5, 2013).
10.5Employment Agreement, dated as of August 16, 2013 and effective August 19, 2013, by and between NeoStem, Inc. and Robert Dickey IV (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K dated August 19, 2013).
10.6Amendment dated August 14, 2013 and effective August 19, 2013, by and between NeoStem, Inc. and Larry A. May (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K dated August 19, 2013).*
101.INSXBRL Instance Document***
101.SCHXBRL Taxonomy Extension Schema***
101.CALXBRL Taxonomy Extension Calculation Linkbase***
101.DEFXBRL Taxonomy Extension Definition Linkbase***
101.LABXBRL Taxonomy Extension Label Linkbase***
101.PREXBRL Taxonomy Extension Presentation Linkbase***
_______________

*Filed herewith.
**Furnished herewith.
***Users of this interactive data file are advised pursuant to Rule 406T of Regulations S-T that this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.


3630
Index

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on November 7, 2013May 8, 2014.
   
  NEOSTEM, INC.
   
By:  /s/ Robin L. Smith, M.D.
Name: Robin L. Smith, M.D.
 Title: Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
     
Signature Title Date
/s/ Robin L. Smith, M.D.
Robin L. Smith, M.D.
 
Director, Chief Executive Officer and
 Chairman of the Board (Principal Executive Officer)
 November 7, 2013May 8, 2014
/s/ Robert Dickey IV
Robert Dickey IV
 Chief Financial Officer (Principal Financial Officer) November 7, 2013May 8, 2014
/s/ Joseph Talamo
Joseph Talamo
 
Vice President, Corporate Controller and Chief
 Accounting Officer (Principal Accounting Officer)
 November 7, 2013May 8, 2014




3731